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Abstract
The use of veterinary drugs and zootechnical feed additives has become widespread in 
modern agricultural practice. Each Member State of the European Union is required to 
monitor for residues of these compounds in animal tissue and animal products that are 
intended for human consumption. From 1st September, 1999, the use of the zootechnical 
feed additives, carbadox and olaquindox is not permitted within the European Union. An 
electrospray LC-MS-MS method for the confirmation of carbadox and olaquindox in meal 
is described. The method was developed for contamination level analysis of each drug in 
feed. An electrospray LC-MS-MS method for the carbadox marker residue in tissue, 
quinoxaline-2-carboxylic acid, is described. The method was validated over the range 3.0 - 
300 pg kg"1, to reflect the range of concentrations measured in NI National Surveillance 
Scheme samples. The Decision Limit and Detection Capability are also described. This 
tissue method was applied to the pharmacokinetic study of pigs exposed to housing 
contaminated by carbadox treated animals. Tentative criteria are suggested for a method 
that enables National Authorities to discriminate between deliberate use and accidental 
exposure to contaminated housing. A dual electrospray LC-MS-MS method for the 
carbadox and olaquindox tissue marker residues, quinoxaline-2-carboxylic acid and 
methyl-3-(quinoxaline-2)-carboxylic acid, respectively, are presented. The method was 
validated over the range 3.0 - 150 pg kg"1, to reflect the range of possible concentrations to 
be measured in Northern Ireland National Surveillance Scheme samples. The Decision 
Limit and Detection Capability are also described. All the presented methods have been 
validated according to current European Union criteria for veterinary residue analysis 
(European Commission Decision 2002/657/EC). All the described methods are to be 
applied to the statutory analysis of samples taken in Northern Ireland.
- IV-
Publications
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., 2003, Development and 
validation of a method for confirmation of carbadox and olaquindox in porcine 
feedingstuffs using LC - electrospray MS-MS. Food Additives and Contaminants, 
submitted.
Hutchinson, M. J., Young, P. B., Hewitt, S. A., Faulkner, D., and Kennedy, D. G.,
2002, Development and validation of an improved method for confirmation of the 
carbadox metabolite, quinoxaline-2-carboxylic acid, in porcine liver using LC- 
electrospray MS-MS according to revised EU criteria for veterinary drug residues. The 
Analyst, 127, 342-346.
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., 2003, Quinoxaline-2-carboxylic 
acid in pigs: criteria to distinguish between illegal use of carbadox and environmental 
contamination. Food Additives and Contaminants, accepted.
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., 2003, Development and 
validation of a dual method for the confirmation of quinoxaline-2-carboxylic acid (a 
metabolite of carbadox) and methyl-3-quinoxaline-2-carboxylic acid (a metabolite of 




ADI acceptable daily intake
amu atomic mass units
AOZ 3-amino-2-oxazolidinone
APCI atmospheric pressure chemical ionisation
ASMS American Society for Mass Spectrometry
°C degrees centigrade
°C min' degrees centigrade per minute
C,8 octadecylsilyl derivatised silica
CBX carbadox
CCa limit of analyte quantification
ccp limit of analyte determination
Cl chemical ionisation
CID collision induced dissociation
CRL Community Reference Laboratory
CSD Chemical Surveillance Department
CV coefficient of variation
d7-MQCA deuterated methyl-3-quinoxaline-2-carboxylic acid -
containing seven deuterium atoms
d4-QCA deuterated quinoxaline-2-carboxylic acid - containing four
deuterium atoms
DAL differential action limit










ELISA enzyme linked immunosorbent assay
et al. and others
EU European Union
eV electron volts
FAO Food and Agriculture Organisation of the United Nations
Fig. Figure
g gram(s)
g acceleration due to gravity








HPLC high performance liquid chromatography
HR-MS high resolution - mass spectrometry
-VII-
IP identification point(s)





lb'1 litres per hour
LC-MS liquid chromatography - mass spectrometry
LoQ limit of quantification
LR-MS low resolution - mass spectrometry
Ltd. Limited
M moles per litre
mbar millibars of pressure
mg milligram(s)
mg kg'1 milligrams per kilogram
mg kg'1 day'1 milligrams per kilogram per day
mg ml'1 milligrams per millilitre
mg l'1 milligrams per litre
MIC minimum inhibitory concentration
min minute(s)
ml millilitre(s)
ml min'1 millilitres per minute
mm millimetre(s)
mM millimoles per litre
monoxy-CBX monoxycarbadox
monoxy-OLQ monoxyolaquindox




























maximum residue limit 
multiple reaction monitoring 
minimum required performance limit 
millisecond(s)
tandem mass spectrometry - mass spectrometry
molecular weight









No Observable Effect Level 


































National institute of public health and environment in The
Netherlands
revolutions per minute
relative standard deviation also known as the coefficient of 
variation
standard deviation




standard error of the mean 
selected ion monitoring 
solid phase extraction 
species
relative standard deviation 
time
trifluoroacetic acid 









g'‘ micrograms per gram
^g kg’ micrograms per kilogram




VSD Veterinary Sciences Division
v/v volume per unit volume
w/v weight per unit volume
w/w weight per unit weight














1.2. Veterinary drugs 4
1.2.1. Antibacterial drugs 4
1.2.2. Antiprotozoal drugs 4
1.2.3. Antiparasitic drugs 5
1.2.4. Administration of veterinary drugs 6
1.3. Veterinary drug residues 7
1.4. Causes of veterinary drug residues 9
1.4.1. Failure to obey withdrawal time 9
1.4.2. Cross contamination of feed 10
1.4.3. On-farm contamination 11
1.4.4. Illegal or improper use of drugs 11
1.5. Risks of veterinary drugs and their residues to public health 12
1.5.1. Acute pharmacological effects 13
1.5.2. Allergies 13
-XII -
1.5.3. Carcinogenic and mutagenic effects 14
1.5.4. Antibiotic resistance 15
1.5.5. Environmental effects 16
1.6. Establishment of maximum residue limits 17
1.7. European Union legislation concerning veterinary drugs 18
1.7.1. European Union Council Regulation 2377/90 19
1.7.2. European Union Council Directive 96/23/EC 20
1.8. Application of legislation in Northern Ireland 21
1.8.1. National Surveillance Scheme for Northern Ireland 22
1.8.2. Meat Inspection Scheme 23
1.8.3. Pig Testing Scheme 23
1.9. Chemical surveillance methods 23
1.9.1. Screening methods 24
1.9.2. Confirmatory methods 25
1.10. Liquid chromatography - mass spectrometry 26
1.10.1. Electrospray 27
1.10.2. LC-MS considerations 28
1.10.3. Application of LC-MS to the analysis of veterinary drug 30
residues in Northern Ireland
1.11. European Union legislation concerning LC-MS method 32
development
1.11.1. Compound identification 33
1.11.2. Recovery 36
1.11.3. Repeatability 36
1.11.4. Within-laboratory reproducibility 36
1.11.5. Decision Limit (CCa) 37




1.13.1. Chemistry and physical properties 40
1.13.2. Absorption, metabolism and pharmacokinetics 41
1.13.3. Growth promoting action 43
1.13.4. Veterinary use and clinical symptoms 46
1.13.5. Mutagenic properties and antibacterial activity 48
1.13.6. European Union legislation concerning carbadox 50
1.13.7. Quinoxaline-2-carboxylic acid 52
1.14. Olaquindox 53
1.14.1. Chemistry and physical properties 53
1.14.2. Absorption, metabolism and pharmacokinetics 53
1.14.3. Growth promoting action 55
1.14.4. Veterinary use and clinical symptoms 56
1.14.5. Mutagenic properties and antibacterial activity 57
1.14.6. Phototoxicity 58
1.14.7. European Union legislation concerning olaquindox 61
1.14.8. Methyl quinoxaline carboxylic acid 62
1.15. Analytical methods 63
1.15.1. Detection of carbadox in feedingstuffs and tissue 63
1.15.2. Detection of quinoxaline carboxylic acid in tissue 66
1.15.3. Detection of olaquindox in feedingstuffs and tissue 68




Simultaneous determination of carbadox and olaquindox in animal 






2.2.3. Spiking solutions for validation 76
2.2.4. Equipment 76
2.2.5. Sample extraction 77
2.2.6. LC-MS-MS analysis 78
2.3. Results and discussion 79
2.3.1. Tandem MS analysis of carbadox and olaquindox 79




Determination of the carbadox metabolite, quinoxaIine-2-carboxylic 







3.2.3. Tissue extraction 93
3.2.4. Tandem MS analysis 94
3.2.5. GC-MS analysis 95
3.3. Results and discussion 95
3.3.1. Tandem MS analysis of quinoxaline carboxylic acid 95
3.3.2. Method performance characteristics 96
3.3.3. Correlation of the described method with the standard 105




Quinoxaline-2-carboxylic acid in pigs: criteria to distinguish between the 
illegal use of carbadox and environmental contamination
4.1. Introduction 108
4.2. Experimental 110
4.2.1. Experiment 1. Depletion of carbadox from pigs 112
4.2.2. Experiment 2. Exposure of untreated pigs to carbadox- 110
contaminated housing
4.2.3. Determination of quinoxaline carboxylic acid concentrations 111
in liver, kidney, muscle, urine and bile
4.3. Results 112
4.3.1. Experiment 1. Depletion of carbadox from pigs 112
-XVI -
4.3.2. Experiment 2. Exposure of untreated pigs to carbadox 112
contaminated housing
4.3.3. Urine : liver quinoxaline carboxylic acid concentration ratio 113
4.4. Discussion 116
4.4.1. Quinoxaline carboxylic acid in pigs exposed to 116
environmental contamination
4.4.2. Possible criteria for distinguishing between abuse and 118
contamination




Simultaneous determination of the carbadox metabolite, quinoxaIine-2 
carboxylic acid and the olaquindox metabolite, methyl-3-quinoxaline-2 
carboxylic acid in porcine liver using liquid chromatography 





5.2.3. Sample extraction 126
5.2.4. Tandem MS analysis 127
5.3. Results and discussion 129
5.3.1. Tandem MS analysis of quinoxaline carboxylic acid and methyl 129
quinoxaline carboxylic acid
- XVII -






6.2. Confirmation of carbadox and olaquindox in feeds 144
6.3. Confirmation of quinoxaline carboxylic acid in tissue 146
6.4. Bioavailability of quinoxaline carboxylic acid in pigs 147
6.5. Dual confirmation of quinoxaline carboxylic acid and







Since the 1960s there have been dramatic increases in the range and diversity of foods we 
eat through global marketing and expanded international trade. This has led to massive 
changes in the methods of food production - no longer is it possible to rely on small 
producers to meet the demands of the population and still have a viable export market. 
Producers now strive to use high intensity, highly efficient, and low cost methods of 
production to provide for the current demand. It was the unexpected discovery in the 
1950s that antibiotic drugs increased growth rates and improved the efficiency of food 
utilisation in pigs and chickens that has led to their use as growth promoters ever since. 
This has greatly aided the evolution of such intensive production methods for livestock. 
The discovery of the growth promoting action was through their use at sub-therapeutic 
levels, mainly as additives to feed. Such use was as a prophylactic for the prevention of 
common diseases (to which intensively reared animals are susceptible) and the rapid 
spread of infectious disease. A wide range of drugs is available to veterinarians and 
producers for use in modem agriculture. They are used for the management of specific 
disease states, treatment of parasitic infection, prevention of inflammatory reactions, and 
many others. However, since the 1950s they have found widespread use as growth 
promoters and prophylactics.
Since the early 1980s, there has been greatly increased public awareness of health issues 
in general, as well as a growing interest in animal health welfare and ethical issues. 
Concern has been expressed regarding the impact on public health from the use of drugs in 
animals for human consumption, and the intensive methods used in modem food 
production. These concerns arise from consumer confidence in the wholesomeness of food 
having been destabilised through several large public health scandals. One good example
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of this has been the Salmonella outbreaks in eggs in the early 1990s, which decreased egg 
consumption over the next several years. The public is now more aware than ever that 
what they eat is not necessarily either wholesome or good for their health. Reports as early 
as 1969 concluded that the administration of antibiotics to farm livestock, particularly at 
sub-therapeutic levels, posed hazards to both human and animal health (Swann, 1969). 
Many reports have also been published linking resistant strains of bacteria and allergic 
reactions to veterinary drug residues, as well as queries over their long-term physiological 
effects in humans, through the consumption of such residues. This has led to much 
criticism and debate in the media over modem farming methods and the use of growth 
promoting products in agriculture.
Contrary to popular opinion, agricultural use of antibiotics is extensively regulated. 
Legislation has been in place since the mid. 1970s in the European Union (EU), governing 
the use of veterinary medicines and zootechnical feed additives. Legislation, to which all 
Member States within the EU must adhere, is in place concerning the monitoring of 
residues of such products, to guarantee the safety and quality of animals and animal 
products for human consumption. Each country within the EU is responsible for its own 
residue testing, producer sampling, and National Surveillance Schemes, all of which must 
comply with current EU regulations. Such systems involve the expenditure of 
considerable resources in terms of finance and labour per annum. The British residue 
surveillance scheme cost the government £3.6 million in 2001 for statutory testing alone 
(Veterinary Residues Committee, 2001). Active research is also carried out to improve and 
develop new analytical methods for the detection of drug residues, plus investigations into 
the pharmacokinetics of these drugs, which can help analysis and enforcement of any 
current bans on use.
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1.2. Veterinary drugs
In agriculture, either a bacterial or a parasitic agent is the most common cause of disease. 
Anti-infective drugs are largely classified into groups according to their function - as 
either an anti-infectious or an anti-parasitic agent, rather than by their chemical structure 
as in human pharmacology. Within these groups, both specific function and chemical 
structure may further sub-classify the drugs. Anti-infective agents are classed into 
antibacterial, antifungal, antiviral, and antiprotozoal agents. From the point of view of 
drug residues and monitoring, antibacterials and antiprotozoal drugs are the most 
important, due to the sheer volume of their use.
1.2.1. Antibacterial drugs
Antibacterial drugs, which include natural, semi-synthetic and synthetic compounds, 
consist of bactericidal agents that kill bacteria, and bacteriostatic agents that inhibit 
cellular neogenesis allowing the immune response to kill the infecting bacteria. They are 
classified into 10 major groups: (3-lactams, tetracyclines, aminoglycosides, macrolides and 
lincosamides, amphenicols, sulphonamides and potentiated suphonamides, nitrofurans, 
nitroimidazoles, quinolones, and ‘other’ drugs. Larger groups such as the (3-lactams have 
been further sub-divided on their function against disease states. Commonly used 
antibacterial drugs include penicillin, tetracycline, neomycin, and trimethoprim all of 
which have use in both veterinary and human medicine.
1.2.2. Antiprotozoal drugs
Antiprotozoal agents are classified into several major groups - based on the causative 
protozoa. Anticoccidials (e.g. monensin, narasin and lasalocid) are active against Eimeria
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or Isospora spp. Drugs for histomoniosis (e.g. dimetridazole and nifursol) which are active 
against Histomonas meleagridis. Drugs for trichomoniosis (e.g. ronidazole and 
camidazole) are active against trichomonads. Drugs for babesiosis (e.g. Imidocarb 
dipropionate and diminazine) are active against Babesia spp. Drugs for giardiosis (e.g. 
fendendazole) are active against Giardia spp. Drugs for hexamitiosis (e.g. dimetridazole) 
which are active against Hexamita meleagridis. Drugs for leishmaniosis (e.g. pentamidine 
and allopurinol) are active against Leishmania spp. Drugs for theileriosis (e.g. 
buparvaquone and chlortetracycline) are active against Theileria spp. and drugs for 
typanosomosis (e.g. diminazine).
There exists some crossover between drug groups and classes and they are by no means 
exclusive. For example nitroimidazoles can be used both as an antibacterial agent in the 
treatment of infections caused by anaerobic bacteria as well as in the treatment of 
giardiasis. 4 -Hydroxyquinolones such as oxolinic, pipemidic and nalidixic acid can be 
used against gram-negative bacterial infections as well as in specific protozoal infection.
1.2.3. Antiparasitic drugs
Antiparasitic agents are a group of drugs used in the treatment and control of parasitic 
infections caused by protozoa, helminths, and arthropods. These are used as either 
endoparasiticides, for the treatment of internal parasitic infections or ectoparasiticides, for 
the treatment of external parasitic infections. They are classified according to the causative 
helminth and are split into 3 groups: drugs for nematodes (roundworm), drugs for cestodes 
(tapeworm), and drugs for trematodes (flukes). These agents vary substantially in 
chemical structure and mode of action. They include avermectins, milbemycins, 
benzimidazoles, imidazothiazoles, and organophosphates. These same agents and others,
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such as benzoyl urea derivatives and carbamates, are also used as ectoparasiticides via 
suspension in topical and dipping solutions or as powders.
1.2.4. Administration of veterinary drugs
There is great variation in the routes of administration of these veterinary medicines - 
muscular or subcutaneous injection, implanted pellet, oral drenching, bolus, or pour on 
preparations. The most commonly used route of administration is oral, achieved by 
incorporating the medication in milk replacer, water, or feed. Low medication levels of 
antibiotics have been used in livestock production to improve feeding efficiency and 
increase weight gain. Estimates of the beneficial effects vary, but such sub-therapeutic use 
in young swine has been reported to increase the average daily feed efficiency from 6 to 
8% and the average daily weight gains from 10 to 23% (Prescott, 1997). Sub-therapeutic 
levels are also used as preventative measures against commonly occurring diseases. For 
example, tetracyclines have been used in the poultry industry to prevent bacterial 
infections in flocks. Higher medication levels can be used above a bacterium’s Minimal 
Inhibitory Concentration (MIC) as treatment for a disease state.
The worldwide use of veterinary drugs as feed additives is extensive, with the market for 
antibacterial and anticoccidial worth several billion dollars a year. In addition to their legal 
use as licensed medicines, unscrupulous producers have been found to use some 
compounds illegally as growth promoters. For example, the P-agonist clenbuterol has 
growth promoting effects when used at five times the recommended concentration for the 
treatment of respiratory disease. A major cause of public concern in the past few years is 
the presence of veterinary drugs, their residues, and other chemical contaminants in 
animals for human consumption at the time of slaughter, as well as in milk and eggs.
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Consequently, the potential exists that this may give rise to human health problems, 
possible side effects or illnesses as the long-term toxicological effects are not known, in 
addition to increases in the incidence of antibiotic resistant bacteria. Incidences of food 
related scares are usually well reported in the media as they are seen as human-interest 
stories.
1.3. Veterinary drug residues
The EU has defined veterinary drug residues as:
All pharmacologically active substances, whether active principles, excipients or 
degradation products, and their metabolites which remain in food stuffs obtained from 
animals to which the veterinary medicinal product has been administered.” (European 
Commission, 1990a).
EU Council Regulation No 2377/90 (see Section 1.7.2.) lists the maximum legally 
permitted concentration of residues resulting from the use of a veterinary medicinal 
product that is acceptable by the EU in animal tissue. This is known as the Maximum 
Residue Limit (MRL) and has been established due to concerns over both short and long­
term effects on human health. MRLs are only set for compounds that are legally licensed 
for use within the community. For previously unlicensed compounds i.e. compounds that 
have had their licence withdrawn, no MRL is set, as any traces of such residues are not 
permitted in animal tissue.
Residues resulting from the use of a veterinary medicinal product are normally formed 
when the compound is metabolised into a water-soluble product to allow excretion via
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urine or bile / faecal matter. Drug metabolism is normally divided into two parts: Phase I 
and Phase II.
Phase I or functionalisation reactions
Phase I is commonly thought of as a preparation step for Phase II. These include 
oxidation, reduction, hydrolysis and hydration reactions. The majority of these are carried 
out by the microsomal mixed-function oxidase systems that are cytochrome P450 
dependent in the endoplasmic reticulum of cells most notably in the liver, kidney, lung 
and intestine. The final product usually contains a chemically reactive functional group 
that allows reaction with phase II enzymes. For the clearance of some drugs phase I 
metabolism is sufficient to allow excretion.
Phase II or conjugation reactions
Phase II usually involves formation of a water-soluble product that can be secreted in the 
bile or urine. This is the true ‘detoxification’ step. This involves conjugation with sugars, 
amino acids, fatty acids and cholesteryl esters, as well as sulfation, methylation, 
acetylation, and condensation reactions.
Some drugs do not require Phase I or Phase II reactions; chemical catalysis can occur by 
endogenous metabolism in the target tissue or organ that converts the parent compound to 
a water-soluble product. Clearance of the product is usually via kidney or the liver; the 
specific route largely influenced by molecular weight (m.w.). Drugs with m.w. less than 
300 are largely secreted in the urine, those larger than m.w. 300 are largely secreted in the 
bile. As a result of these reactions, metabolites may have different chemical and biological 
properties than that of the parent drug. Different species may also generate more of one
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metabolite through differing enzymic concentrations or iso-enzymatic forms. These 
factors can affect the half-life / clearance rate of a metabolite. Consequently, residues of 
compounds can exist in one tissue type for several days and in another for several weeks, 
even after the parent compound has been excreted from the system. A good example of 
this is the antimicrobial furazolidone, which has been used in poultry production as a 
growth promoter and prophylactic feed additive. Furazolidone has a very short biological 
half-life in vitro and in vivo, being rapidly converted within 4-6 hours to metabolites 
containing a 3-amino-2-oxalidinone (AOZ) side-chain that are protein bound. These AOZ 
residues have been detected in porcine tissues 6-7 weeks after cessation of treatment 
(McCracken et a/., 1997).
1.4. Causes of veterinary drug residues
Providing that a licensed drug is used as per product licence and the correct withdrawal 
times are obeyed before slaughter, violative levels of residues should not occur in animals 
or animal products for human consumption. However, such concentrations of residues can 
occur before slaughter due to a number of reasons:
1.4.1. Failure to obey withdrawal time
EU legislation lists MRLs for each licensed veterinary drug (European Commission, 
1999). The withdrawal period is the interval that must elapse (after the cessation of 
treatment) before an animal may be slaughtered and any derived products used for human 
consumption. This period is designed so that any residues resulting from administration of 
medication will be below the MRL, at the time of slaughter. The Animals and Animal 
Products (Examination for Residues and Maximum Residues Limits) Regulations 1997 
implement these regulations in the United Kingdom (UK). These state that an animal may
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not be supplied or slaughtered if the withdrawal period for a legally administered 
veterinary product has not been obeyed. Withdrawal times are stated individually by 
species, as differing physiology can increase or decrease the rate at which residues are 
cleared from tissue. Withdrawal times can also vary depending on the individual 
formulation i.e. two products containing the same concentration of an active principle can 
have differing withdrawal periods.
To comply with the withdrawal time, unmedicated rations must be supplied to the animals 
throughout this period. A producer may consider this a needless expense, or this period as 
excessive or inconvenient as it delays the sale of livestock. This can lead to no and/or a 
reduced withdrawal time being followed, resulting in residue concentrations above the 
maximum permissible levels at slaughter.
1.4.2. Cross contamination of feed
After the preparation of medicated feed in feed mills, subsequent batches of feed may 
contain sub-therapeutic levels of the drug used. This may still occur after flushing of the 
production line, due to the electrostatic properties of the drug formulation. One study with 
the coccidiostat, monensin, widely used in the broiler chicken industry, reported levels 
greater than 5 % of the therapeutic dose in 9 of the 40 withdrawal meals tested from one 
feed mill. These sub-therapeutic levels may be enough to cause ‘violative’ residues in the 
tissues, eggs or milk of an animal if fed such contaminated rations during a withdrawal 
period (Kennedy et al., 1998c). Another study tested 397 feedingstuffs and 11 premixes of 
which 35.2 % were found to contained undeclared antimicrobials. The most frequently 
identified were chlortetracycline, sulphonamides, penicillin, and ionophores. All the 
contaminating concentrations of sulphadimidine detected would have been sufficient to
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cause tissue residue levels above the MRL, if fed to animals as withdrawal rations prior to 
slaughter (Lynas et al., 1998). Manufacturers have addressed these problems by producing 
granular medicated preparations that have greatly reduced electrostatic properties. This 
reduces the degree of carryover, but does not eliminate the problem. For example the 
introduction of a granular form of medicated premix for the coccidiostat lasalocid reduced 
the incidences of lasalocid residues in eggs in Northern Ireland, but did not eliminate the 
problem entirely (Kennedy et al., 1998a).
1.4.3. On-farm contamination
On-farm contamination may occur by the same means as in industry (see Section 1.4.2.), if 
the medicated feed is prepared on-site and inadequate purging of the system takes place. 
Short-term exposure before slaughter of previously unmedicated animals to housing that 
has contained treated animals has been shown to result in residues in tissue. Residues of 
furazolidone, a nitrofuran antibacterial effective against Escherichia coli and Salmonella 
spp. infections in pigs, have been found in unmedicated pigs following exposure to a 
cleaned housing that had previously contained pigs undergoing furazolidone medication 
(McCracken et al., 1997). Similar findings have been reported for residues of 
sulphadimidine, used in intensive pig production for the prevention of many respiratory 
and gastrointestinal diseases (Elliott et al., 1994b).
1.4.4. Illegal or improper use of drugs
Improper use of a drug above the recommended therapeutic concentration, as listed in the 
current UK Veterinary formulary (Anonymous, 2001), can lead to residues existing even 
after the observation of the correct withdrawal time for the drug. This may also be applied
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to the use of a veterinary medicine authorised for use in another animal species or for 
another condition in the same species, known as ‘Off-label use’. Illegal use of drugs, such 
as hormones for the purpose of increasing live-weight gain, may give rise to residues at 
slaughter even after a significant withdrawal period (Meyer and Rinke, 1991).
Annex I and III of EU Council Regulation No 2377/90 lists the MRL concentrations for 
all permissible veterinary compounds. If a producer can give no valid reason to justify a 
result exceeding the MRL set for a compound, further sampling maybe carried out. This 
can lead to condemnation of animals and ultimately prosecution in a court of law. The 
same criterion applies following a positive result for a banned drug (compounds which are 
listed in Annex IV of the same regulation), and other unlicensed substances (e.g. 
zootechnical compounds that have had their licences withdrawn).
1.5. Risks of veterinary drugs and their residues to public health
In Great Britain (GB) in 2001, -39,000 samples of meat were collected and tested under 
the National Surveillance Scheme (Veterinary Residues Committee, 2001). Of the 
-44,000 analyses performed, only 155 revealed samples which contained veterinary drug 
residues above the MRL or Differential Action Level (DAL). NI operates a separate 
sampling system linked to GB. In 2000, 3,334 samples of meat were taken for analysis 
under the NI national plan for veterinary drug residue surveillance. Of these 3320 (99.6%) 
were found to be free from violative residues. 14 (0.4%) of these samples contained 
residues in excess of the MRL or DAL (Veterinary Medicines Directorate, 2000). Though 
the problem of residues is statistically small, it still poses a significant threat to public 
health. With the wide range of veterinary drugs and products available to producer, the 
potential exists for chemical residues to be present in animal products destined for human
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consumption, leading to possible short and long term pharmacological side effects. 
Though the number of assessed positive samples is low, each positive is a representative 
sample taken randomly from a large group of animals at slaughter, the derived products of 
which can be consumed by a significant number of the population. These veterinary drugs 
and their residues have been shown to give rise to several potential threats to the consumer 
and producer.
1.5.1. Acute pharmacological effects
Clenbuterol, popularly known as ‘Angel Dusf, is the most commonly abused of the 
p-agonists. Its action as a growth promoter requires concentrations in excess of five times 
the recommended therapeutic dose for respiratory disease, for extended periods (>30 
days). This alters the fat to muscle deposition ratio and increases the live weight (Ricks et 
al., 1984), consequently increasing the price per head of livestock for the producer at sale. 
Such elevated medication levels can result in accumulation of significant concentrations of 
the drug in edible tissues (Meyer and Rinke, 1991). High concentrations of such drug 
residues in animals and animal products have resulted in the poisoning of consumers, 
giving rise to symptoms such as muscle tremors, palpitations, tachycardia and myalgia 
that have lasted up to forty hours (Martinez-Navarro, 1990; Pulse et al., 1991). Similar 
risks may be associated with the consumption of injection sites and implanted pellets, 
which contain high local concentrations of the drug in the tissue.
1.5.2. Allergies
Reactions to drugs and their residues include photosensitivity, photoirritation, 
inflammatory reactions, and in severe cases - anaphylactic shock. Such possible allergic
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reactions must be differentiated from reactions to natural food constituents, such as to the
oils present in nuts. P-Lactams, though relatively non-toxic, may be responsible for most 
of the reported human allergic reactions to antibiotics. As early as 1959, allergic reactions 
to penicillin and its derivatives were recognised. Penicillin was used extensively at that 
time to treat mastitis in dairy animals. As a result of non-compliance with recommended 
withdrawal times, penicillin had become a common adulterant in marketed milk. Allergic 
reactions, such as skin rashes, to contaminated milk were recognised at this time by public 
health authorities (Zimmerman, 1959). Skin allergies have been shown to occur through 
direct contact with pure drug in feed mills or through ‘on-farm’ handling of medicated 
feed without protective equipment. The use or exposure of humans to several drugs, 
particularly diuretics, neuroleptics and antibiotics, has been well documented to induce 
photoirritation and/or photoallergic reactions (Boulitrop-Morvan et al., 1993; Mizuma et 
al., 1999; Tokura, 1998). Of the antibiotics, quinolones and fluoroquinolones have the 
greatest potential for inducing photoirritancy and have been documented in a variety of 
experimental studies (Christ and Esch, 1991).
1.5.3. Carcinogenic and mutagenic effects
Veterinary drug residues occur in tissue at such low levels that they rarely pose chronic or 
long-term hazards to human health. Although the parent compounds of certain drugs may 
be relatively innocuous and chemically inert (though clinically active), their metabolites 
have been shown to exhibit carcinogenic and mutagenic effects in laboratory animals. 
Aromatic hydrocarbons as well as many cyclic compounds can be metabolised by 
cytochrome P450 and epoxide hydrolyase to form electrophilic diol-epoxide metabolites 
that are capable of covalent bonding with nucleic acids i.e. chemical carcinogenesis. For 
example, nitroimidazoles such as metronidazole, dimetridazole and ronidazole, have been
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shown to be carcinogenic in bacteria due to suspected reductive 5-nitro metabolites 
(Voogh et al., 1974). Dimetridazole, ronidazole and ipronidazole medication has also been 
linked to increased incidence of mutation and tumour formation in rats (WHO/FAO, 
1989). The hormone oestradiol-17-P is prohibited from use in the EU, as a substantial 
body of evidence exists suggesting that it is a carcinogen and that it possesses tumour- 
promoting effects (European Commission, 1996b). The hormones testosterone, 
progesterone, trenbolone acetate, zeranol and melengestrol acetate are also prohibited on 
suspicion of having similar effects, though they are still legally permitted in the USA. The 
EU recently upheld the prohibition of such substances, as they have not been able to give a 
quantitative estimate of the risk to consumers. The EU considers the possible long-term 
exposure to even low levels of veterinary residues with possible carcinogenic, mutagenic 
or genotoxic effects, to be an unacceptable potential risk to the consumer.
1.5.4. Antibiotic resistance
A major potential risk exists with the widespread use of antibiotics in livestock. There is 
the possibility of drug resistant pathogens occurring through natural selection, and 
subsequently that these animal pathogens may be transmitted to man. Zoonotic infections 
do exist, such as Campylobacter jejuni. Salmonella spp., and Esherichia coli 0157:H7 
(‘the hamburger pathogen’). Such ‘super bugs’ have led to public health scares and the 
closure of hospital wards. Of other concern is the possible emergence of antibiotic 
resistant non-pathogens that can colonise humans or livestock gut flora for extended 
periods with no adverse effects. This gives rise to the potential transfer of resistance to 
bacteria capable of causing pathogenesis through the well-documented swapping of 
genetic elements such as plasmids. If such resistant strains were to occur in livestock, the 
possibility exists that resistance could be passed to human pathogens. There also is a risk
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that administration of an antimicrobial used only in veterinary medicine could lead to the 
selection of strains resistant to antibiotics in human medicine. For example, in April 1997 
the EU suspended the use avoparcin, a glycopeptide antibiotic, never used in human 
medicine, following the publication of results showing that its use was closely associated 
with the occurrence of vancomycin-resistant Enterococcus faecium in food animals 
(Moller Aarestrup et al., 1996). Such was the concern over the possible transfer of 
resistance to human pathogens, that a Community ban was initiated, although the EU 
Scientific Committee for Animal Nutrition (SCAN) had already concluded in 1996 that 
there was no direct evidence of any link Though the latent risk for antibiotic resistant 
pathogens exists as a result of the use of veterinary drugs in livestock, they cannot wholly 
be blamed for occurrence of resistant strains that are of current medical concern. The high, 
routine use of antibiotics in human medicine must take the largest portion of the blame, 
through the ‘empiricaF prescribing within community practice and prescribing ‘blind’ on 
presumption via the description of symptoms.
1.5.5. Environmental Effects
A significant proportion of veterinary drugs that are administered to animals is ultimately 
spread in the terrestrial and aquatic environments (Halling-Sorensen et al., 1998). The 
exact concentration of chemical residues that pass through an animal is dependent on 
species and the route of administration of the drug. For example a drug given orally has a 
higher chance of being present in faecal matter due to incomplete absorption in the 
gastrointestinal tract e.g. ampillicin. Intravenous injection is much less likely to do so as it 
bypasses the absorption in the gut wall, passing directly into the systemic circulation. Such 
compounds may persist in the environment for days or months depending on the 
compound in question and the temperature (Gavalchin and Katz, 1994). Detrimental
- 16-
effects can be observed on non-target organisms in the soil that are required for natural 
environmental processes such as recycling of animal waste, nitrogen fixation, etc. 
Persistent residues can be transferred into the aquatic environment through surface run-off 
or by leeching of the soil profile, as is the case for several other chemicals such as 
pesticides. High concentrations in an aquatic system may ultimately lead to significant 
effects on algal and cyanobacterial populations (Halling-Sorensen, 2000), fresh water 
crustaceans (Wollenberger et ai, 2000), and other fresh-water organisms (Canton and Van 
Esch, 1978). Similar antibiotic persistence has been shown to occur in marine sediments 
from the use of antibiotics in aquaculture (Hektoen et al., 1995). In both the aquatic and 
terrestrial environments, there is again the potential for the emergence of resistant species 
through natural selection as previously mentioned (see Section 1.5.4.).
1.6. Establishment of maximum residue limits
The value for the MRL in food within the EU for legally licensed compounds is 
determined in a number of steps. The sponsor of the drug is required to carry out a wide 
range of toxicity, metabolic and depletion studies as part of the approval process for use. 
From these, the tissue from which the drug and its residues deplete the most slowly can be 
determined. The longest remaining metabolite in this tissue usually being named as the 
marker residue for the use of the drug. However, if studies show that a particular 
metabolite of a drug is toxic, an MRL may be established for this instead. Firstly, the 
Acceptable Daily Intake (ADI) in mg kg'1 day'1 for the residue must be determined. This 
value is the concentration of drug that can be consumed per day, during an entire lifetime 
with no appreciable health risk, based on all the known facts at the time. This No 
Observed Effect Level (NOEL) is calculated on the basis of systemic, reproductive, and 
developmental toxicology studies in vitro, and genotoxicity/mutagenicity in vivo. The
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value is taken for most sensitive effect or for the species most likely to show the same 
response as humans. This is then divided by a safety factor, usually 100, to allow for 
variability in extrapolating from animals to humans to give the ADI. This assumes that 
there is a 10-fold range in sensitivity and that humans are 10 times more sensitive than 
animals. The MRL is calculated by dividing the ADI with a theoretical amount of meat or 
animal products consumed daily. These have been established by the World Health 
Organisation (WHO) for various tissues (WHO/FAO, 1989):
1) 50 grams of kidney
2) 100 grams of liver
3) 300 grams of muscle
4) 100 grams of eggs
5) 1.5 litres of milk
If a drug is to have a licence granted for more than one species, withdrawal times must be 
established for the depletion of tissue concentrations below the MRL in each. Different 
MRLs are calculated for various food products, like milk, to ensure that children do not 
consume residues at a concentration exceeding the ADI for the compound in question 
based on reduced bodyweight. An extra 10-fold factor is usually included in the 
extrapolated safety factor.
1.7. European Union legislation concerning veterinary drugs
Veterinary medicines are legally classified into general sales list medicines, pharmacy 
medicines, pharmacy and merchant list medicines, prescription only medicines, and 
controlled drugs. The use, administration, and licensing of such medicines are controlled
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under national and EU regulations. Zootechnical feed additives such as production 
enhancers or coccidiostats are independently controlled and authorised under EU 
legislation, as indicated in the relevant Annex of the current amended version of EU 
Council Directive 70/524/EEC (European Commission, 1970). EU legislation lays down 
requirements and technical details for the detection and monitoring of the residues of these 
compounds. Part of the terms of admission, as an EU Member State is to adhere to these 
directives. EC Council Regulation No 2377/90 governs the legal use of veterinary drugs 
and the residue levels of each that are permitted. The monitoring of these residues and the 
steps that must be taken to guarantee and ensure the quality of import and export products 
to and from the EU are governed by EU Council Directive 96/23/EC.
1.7.1. European Union Council Regulation No 2377/90
This regulation establishes the MRLs in animals and animal products (European 
Commission, 1990a), for the drugs to be monitored listed in EU Council Directive 
96/23/EC (see Section 1.7.1.). These have been split into the Annexes listed below. Each 
monitored substance is listed in one of the following Annexes to the regulations:
Annex I - Pharmacologically active substances for which final MRLs have been set 
e.g. oxytetracycline, ivermectin, and dexamethasone.
Annex II - Substances, which do not need an MRL e.g. caffeine, ethanol, and 
hydrocortisone.
Annex III - Pharmacologically active substances for which provisional MRLs have 
been fixed e.g. erythromycin, streptomycin, and clenbuterol.
Annex IV - Pharmacologically active substances for which no maximum levels can be 
fixed e.g. metronidazole, chloramphenicol, and chlorpromazine.
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As from 1st Jan 2000, substances not listed in Annex I, II, and III cannot be administered 
to food producing animals or used in veterinary medicinal products. Substances listed in 
Annex IV are not considered safe at any level and cannot be used in livestock production. 
Any zootechnical feed additives that have had their licences withdrawn will not come 
under Annex IV and each comes under separate EU legislation.
1.7.2. European Union Council Directive 96/23/EC
This directive (European Commission, 1996c), which superseded EU Council Directive 
86/469/EEC, lays down measures to be taken by Member States to monitor for substances 
with applications of use in the agricultural sector. Annex I lists the groups of substances 
that are required to be monitored. This Annex has been split into two groups of 
substances:
Group A - which are substances having an anabolic effect and unauthorised 
substances. This covers stilbenes and derivatives, antithyroid agents, 
steriods, resorcyclic acid lactones, P-agonists, and compounds included in 
Annex IV to EU Council Regulation No 2377/90.
Group B - which are veterinary drugs, including unlicensed substances used for 
veterinary purposes, and contaminants. This covers antibacterial 
substances, veterinary drugs such as anthelmintics, anticoccidials, 
carbamates and pyrethroids, sedatives, non-steroidal anti-inflammatory 
drugs (NSAIDs), other pharmacologically active substances. Also other 
substances and environment contaminants, such as PCBs, 
organophosphorous compounds, chemical elements, myotoxins, and dyes.
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Annex II of same directive, lists the residue or substance groups to be detected by type of 
animal, feed, or product. Annexes III and IV, lay down the rules for the surveillance of 
such residues by animal type/product, and include sampling strategy, rules, and levels of 
sampling required. The directive also lists administrative measures required of every 
member state:
1) A public body must be assigned to be responsible for co-ordinating, monitoring, 
and inspections.
2) This public body must draw up a national plan for the surveillance of residues in 
compliance with Annex III and IV of the Directive.
3) The results of such a plan must be reported annually to the EC.
4) Each member state must have at least one National Reference Laboratory (NRL), 
to implement quality assurance schemes.
The Annex V of the directive also designates four Community Reference Laboratories 
(CRLs), each of which is responsible for a specific group of residues. The CRTs are there 
to help NRLs implement their quality assurance schemes, promote and co-ordinate 
research and development, provide technical advice and analytical methods, and to train 
analysts from NRLs in both current and new analytical methods.
1.8. Application of Legislation in Northern Ireland
EU Council Directive 90/167/EEC controls manufacture, distribution, and usage of 
medicated feeding stuff (European Commission, 1990b). This has been subsequently 
implemented in NI by Feedingstuffs Regulations (Northern Ireland) 1995 and
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implemented in UK by Medicated Feedingstuffs Regulations 1998. The monitoring of 
veterinary drugs and their residues in both live animals and animal products is required 
under EU Council Directive 96/22/EC (European Commission, 1996b) and 96/23/EC 
(European Commission, 1996c). Control in NI comes under the Animals and Animal 
Products (Examination for Residues and Maximum Residue Limits) Regulations (Northern 
Ireland) 1998, and this act also implements EU Council Regulation No 2377/90. NI 
traditionally exports the majority (~70 - 80%) of its meat and meat products. The Meat 
Hygiene Service inspects all animals submitted for slaughter and a national sampling 
scheme exists to monitor for the presence of drug residues in meat. This surveillance 
scheme is linked to National Surveillance Scheme in GB. Additionally, two other 
intensive surveillance schemes are also operated within NI; the meat inspection scheme 
and the pig testing scheme, to enhance food safety assurance for the export-led industry in 
NI.
1.8.1. National surveillance scheme for Northern Ireland
Under the UK National Surveillance Scheme a specific percentage of the total samples are 
allocated to NI each year, in proportion to the number of the various species slaughtered 
the previous year. In the year 2000, 3,334 samples were taken for analysis under the 
National Surveillance Scheme for NI. Sampling of 1,103 cattle, 604 pigs, 259 sheep, and 
638 poultry was carried out. On-farm sampling of feeding stuffs was carried out on 146 
cattle, 14 pig, and 65 poultry feeds, also taken were 146 milk samples and 153 egg 
samples (Veterinary Medicines Directorate, 2000).
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1.8.2. Meat Inspection Scheme
Under the Meat Inspection Scheme, the on-site government vet can detain animals if 
suspicions of drug treatment are raised, and samples submitted for analysis. Signs of drug 
treatment include adrenal lesions, injection / implant site marks and over-enlarged thyroid 
glands. Any screened samples, which give a positive result for banned compounds or a 
result above the permitted MRL for licensed medicines is subject to confirmatory analysis. 
If the result is upheld after confirmatory analysis, any carcasses linked to the sample are 
condemned and further on-farm sampling of the producer is carried out. Such extended 
sampling can ultimately lead to prosecution.
1.8.3. Pig Testing Scheme
This is a targeted sampling scheme for antimicrobial residues in pigs at slaughter. Samples 
are taken randomly at slaughter and submitted for screening for a wide range of drug 
residues. If a screened sample is positive or above the MRL, the sample is sent for 
confirmatory analysis. Confirmed positives lead to the detaining of up to five animals 
when presented for slaughter by the offending producer. Any positive result leads to 
condemnation of the carcasses and further sampling of any future animals submitted by 
that producer. In the year 2000 in NI, almost 5,000 samples were taken under the pig 
testing scheme, equivalent to 1 in every 250 pigs slaughtered (Veterinary Medicines 
Directorate, 2000).
1.9. Chemical surveillance methods
To facilitate the testing of large numbers of samples generated by National Surveillance 
Schemes and other monitoring programmes, a two-tier system of chemical surveillance is 
generally employed. Samples are first screened in large batches using rapid, high
-23-
throughput procedures with a simple negative or positive for the presence of the drug. In 
the case of positives, such samples are subject to confirmatory methods for unequivocal 
identification and quantification of the analyte. Such methods are slower and involve 
extended clean-up procedures, therefore requiring a longer turn around time.
1.9.1. Screening methods
Due to the large number of samples and to meet the required turn around times (~1 day) 
for the reporting of results, these procedures should be simple, rapid, and inexpensive. 
Sensitivity is required so the presence of an analyte can be detected at MRL levels or 
below for legal substances or a simple positive or negative for trace levels and above of a 
banned substance. The procedures should also have an acceptable probability of false 
negative results (< 5%). Several types exist; the charm receptor assay, based on the 
binding between functional groups on a drug and microbial cell receptor sites, is now 
widely used for the detection of a particular class of antibiotics in milk. Enzyme Linked 
ImmunoSorbent Assays (ELISA) and RadioImmunoAssays (RIA) are also frequently 
employed (Elliott et al., 1994a). Their usefulness is limited by the fact that they require 
unwanted extraction and clean-up steps for tissue samples, and each is applicable only to 
one class of compounds. Time - Resolved Fluorescence ImmunoAssays (TR-FIA) that are 
based on the unique fluorescent properties of lanthanide chelates are well established in 
human medicine as an in vitro screening technique. This technique has now been adapted 
for veterinary in vitro diagnostic screening in the analysis of steroid hormones (Elliott et 
al., 1995) and monensin (Crooks et al., 1998b) in plasma. Most recently it has been 
adapted to the analysis of zeranol in bovine urine (Tuomola et al., 2002). High 
Performance Liquid Chromatography (HPLC), and Thin Layer Chromatography (TLC) 
are also routinely used in screening. Though not often employed. Gas Chromatography -
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Mass Spectrometry (GC-MS) has been used in the screening for anabolic agents and 13- 
agonists (Blanchflower et al., 1993b). The development of biosensor technology has 
created other screening methods that are both rapid and reusable. This technology has 
already been applied as an alternative screening method to ELISA for sulphonamides in 
pigs both in the laboratory (Crooks et ah, 1998a) and on-site at an abattoir (Baxter et al., 
1999). A multi-residue method has also been published using an adapted sensor (Crooks et 
al., 2001). This technology could also lead to the development of procedures that could 
generate real-time results without the need for time consuming clean-up steps and 
deconjugation of analytes, as has already been demonstrated with salbutamol (Elliott et 
al, 1998).
1.9.2. Confirmatory methods
After a positive screening test - unambiguous detection of a compound in the sample is 
required to confirm its presence and quantify it. EU legislation states:
“Confirmatory methods for organic residues or contaminants shall provide information on 
the chemical structure of the analyte. Consequently methods based on chromatographic 
analysis without the use of spectrometric detection are not suitable on their own for use as 
confirmatory methods.” (European Commission, 2002)
This has led to mass spectrometry becoming the method of choice, though 
chromatography linked to other methods such as fluorescence, diode-array detection and 
full scan UV/Vis detection are also suitable. Two types of Mass Spectrometry (MS) are 
frequently employed: Gas Chromatography (GC) and liquid chromatography (LC). GC- 
MS is generally used for thermally stable, non-polar and volatile compounds. Many
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compounds cannot be analysed, as they become unstable due to the high gas, column, and 
MS source temperatures. Less volatile analytes can be derivatised to allow its application. 
Compounds such as steroids can be routinely screened and confirmed using this method as 
they are thermally stable, only require a simple extraction and can easily be derivatised 
(Blanchflower et al., 1993b). LC-MS has no such disadvantages as all separations are 
carried out at ambient temperature. Such separation depends on a number of factors - the 
analyte solubility in mobile phase, chemical functionality of the analyte, pKa value of the 
analyte, HPLC column properties, and the mobile phase. The mobile phase may be 
tailored to one or a mixture of several different analytes to allow specific separations 
and/or to increase or decrease their retention time changing the run time per sample. 
Antibiotics are generally insufficiently volatile, polar or thermally unstable to allow GC- 
MS. Two examples are tetracyclines, which lack the volatility for GC-MS, and 
aminoglycosides that are basic, highly hydrophilic, and thermally labile. Therefore, LC- 
MS has become the preferred method of analysis for such compounds.
1.10. Liquid chromatography - mass spectrometry
HPLC can be linked to MS through various types of interfaces. The separation capabilities 
of HPLC therefore can be linked to the specificity of mass spectrometry, allowing polar, 
thermally labile or non-volatile compounds to be analysed that are not always amenable to 
GC-MS. Several types of interface between the HPLC system and the mass spectrometer 
have been developed over the last 20 years. The most widely used are thermospray, 
Atmospheric Pressure Chemical Ionisation (APCI), and electrospray. Electrospray has 
become the increasing popular method in recent years, not only in the field of antibiotics 
and veterinary drugs, but also in other areas with applications such as peptide and 
nucleotide characterisation etc. Since 1992 it has dominated the annual American Society
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for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics 
(Niessen, 1998). This more than likely goes hand in hand with increasing commercial 
availability and application.
1.10.1. Electrospray
Electrospray like APCI occurs under atmospheric pressure. The HPLC eluate is nebulized 
into electrically charged droplets, from which ions are liberated by ionisation at 
atmospheric pressure and introduced to the mass spectrometer under vacuum. In positive 
mode, the mobile phase eluate passes through a capillary tube that has a high negative 
electric field applied at the tip, pulling the positively charged ions in the liquid towards it. 
The negatively charged ions discharge against the wall of the capillary tube becoming 
neutral. Small electrically charged droplets leave the surface of the mobile phase when 
their electrostatic charge becomes stronger than the surface tension creating a spray. After 
leaving the tip, the solvent in each droplet evaporates creating many smaller daughter 
droplets and a finer spray. These are attracted towards an oppositely charged plate and 
taken into the mass spectrometer under vacuum. When negative ionisation is required, the 
power supply is simply reversed. The capillary tube tip becomes negatively charged, the 
positive ions discharge against the capillary wall leaving only the negative ions to aerosol 
and move towards the positively charged base plate. Like APCI, a high velocity sheath is 
used allowing the handling of solutions that are more aqueous and higher mobile phase 
flow rates - up to 2 ml min "1. This is known as ‘ionspray’ and is commonly incorporated 
into most commercial instruments. Electrospray makes use of the ions present in the 
solution due to evaporation of solvent. The addition of strong acids, for example acetic 
and formic acid at low concentration, or adjustment in pH can greatly help with the 
protonation of polar samples and improve sensitivity for mass spectral analysis in positive
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mode. Triethylamine can serve the same function in negative mode. As with APCI, 
electrospray can also provide CID to increase the number of molecular fragments if 
necessary.
1.10.2. Liquid chromatography - mass spectrometry considerations
Though the analytes in question may be separated satisfactorily using HPLC connected to 
a UV/Vis detector, such a method cannot always be directly transferred for use in 
confirmation by substitution of detection type. The use of phosphate buffers and ion­
pairing agents is common in HPLC. Such compounds are too involatile to allow use with 
the interfaces commonly used in modem LC-MS. The involatile ions in the buffer can 
build up as salt depositions at the tip of the LC interface blocking the flow of the mobile 
phase after a few samples. These buffer ions can also actively suppress ionisation of the 
analyte, decreasing the sensitivity of the method. The development of many new HPLC 
stationary phases, the use of low flow rate narrow bore columns, and the substitution of 
more volatile buffers, allow these problems to be overcome. The organic constituents of 
the mobile phase can also be changed - not only to allow different separation but also to 
enhance the sensitivity of the mass spectrometer. The simple change of the organic phase 
from acetonitrile to methanol has been noted in the laboratory to dramatically increase the 
sensitivity of many methods. The addition of 0.1 - 0.2 % acid in the mobile phase such as 
formic and acetic have also been used to help enhance the ionisation of analytes, improve 
peak shape and increase sensitivity in positive mode. However, such effects are not seen in 
the opposite mode as the positive charge of the acid affect ionisation. Care must be taken 
in the selection of such agents to improve peak shape and sensitivity as they may linger in 
the source of the MS and directly affect the measurement of other analytes. For example, 
if analysis is performed in negative mode after the use of Trifluoroacetic acid (TFA) as an
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ionisation enhancer, the method sensitivity can be compromised, as the TFA will mop up 
the negative ions formed upon ionisation. Such effects have been seen in this laboratory in 
the determination of chloramphenicol after using a mobile containing TFA.
The mass spectrometer can be set to detect the molecular and/or fragment ions of the 
parent compound. The chromatographic separation before analysis plays a large part in 
partitioning interferants of the same molecular weights from the analyte in question. These 
considerations in many methods allow simple clean-up and extraction steps due to the 
degree of selectivity and sensitivity that LC-MS analysis can give. Modem mass 
spectrometers are capable of simultaneously measuring specific separate molecular masses 
with a very short dwell time on each. However, effects from the sample matrix that has 
been carried through the method exist. Ion enhancement, ion suppression, and 
biotransformation of the analyte are all effects encountered even with the selectivity 
possible with modem LC-MS.
Ion enhancement and suppression are the increase or decrease, respectively, of the mass 
spectrometer signal for an analyte due to the composition of the matrix carried over from 
the sample. These can usually be compensated for by the addition of an appropriate 
internal standard at the beginning of sample extraction. The internal standard is preferably 
a deuterated form of the analyte to be measured, exhibiting the same chromatography and 
fragmentation properties as the analyte, but with a molecular weight, several mass units 
higher, that allows differentiation by the mass spectrometer. The internal standard will 
compensate for any losses in extraction of the analyte, as well as for ion enhancement or 
suppression that the analyte undergoes - increasing the accuracy of the method. If an 
internal standard is unavailable, it is common in multi-residue methods to link the
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measurement of an analyte to the internal standard of another similar compound. For 
example, Ferchaud et al. (1998) reported a method for the analysis of testosterone and 
several of its metabolites using dj-methyltestosterone as the single internal standard. 
Alternatively, if no internal standards are available, standards within each run may be 
dissolved in blank extracted matrix to allow for any matrix-related effects on the signal. 
However, this has the disadvantage of increasing the number of samples to be put through 
extraction procedures per run, and will limit the number of unknown samples that can be 
analysed in each run.
1.10.3. Application of LC-MS to the analysis of veterinary drug residues in Northern 
Ireland
LC-MS has been in use as a confirmatory residue method within Veterinary Sciences 
Division (VSD) for more than 10 years. Various methods have been developed and 
published, using a range of LC-MS techniques. Such methods have been applied to the 
statutory testing of samples taken under the National Surveillance Scheme for NI. Some 
examples have been outlined from the first use of thermospray MS in the late 1980s to 
electrospray MS-MS in the present day. One of the earliest thermospray-LC-MS methods 
to be reported from this laboratory was in 1989 and was used for the rapid screening and 
quantification of clenbuterol residues in bovine urine (Blanchflower and Kennedy, 1989b). 
This was closely followed by thermospray methods for the determination in tissue of the 
anthelmintic, nitroxynil (Blanchflower and Kennedy, 1989a), and rafoxanide 
(Blanchflower et al., 1990). Blanchflower et al. (1993a) published a method for the 
determination of chloramphenicol in plasma, milk, and tissue using deuterated 
chloramphenicol as an internal standard. This method used piperonyl butoxide in ethyl 
acetate during tissue homogenisation to inhibit in vitro metabolism of chloramphenicol.
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Analysis was carried out by HPLC linked via a thermospray interface to a Vestec MS 
system. This was followed by a new multi-residue method for the determination of 
penicillin G, penicillin V, oxacillin, cloxacillin and dicloxacillin in milk, kidney and 
muscle samples (Blanchflower et al., 1994). The samples were subject to a simple 
liquid/liquid extraction and analysis by HPLC connected by an electrospray interface to a 
VG Platform MS, operating in negative mode.
McCracken et al. (1995) published a method for the detection of the unstable and rapidly 
metabolised antimicrobial, furazolidone using thermospray MS. The assay was used to 
demonstrate the instability of furazolidone residues both in vitro and in vivo that makes 
such direct detection difficult. This work was subsequently followed up with a method for 
the determination of the protein-bound marker residue of furazolidone - AOZ. In this 
method, AOZ was converted into a nitrobenzaldehyde derivative, NPAOZ, which was 
detected using thermospray MS after HPLC separation on a C|g column (McCracken and 
Kennedy, 1997). This method allowed further studies on the pharmacokinetics and 
bioavailability of furazolidone in pigs (McCracken et al., 1997) and in eggs (McCracken 
et ah, 2001). Through the analysis of AOZ in pigs, it has been shown that it is possible to 
pass AOZ from medicated to unmedicated animals after use of the same housing, thus 
giving rise to the possibility of false ‘positive’ results (McCracken et al., 2000).
Nitroimidazoles are bactericidal drugs that have been used as a broad-spectrum antibiotic 
in the poultry and cattle industries, but are now banned from use within the EU. Few 
methods have been published for the analysis of these compounds. Cannavan and 
Kennedy (1997) published a method for the determination of dimetridazole (DMZ) in both 
poultry tissue and eggs, using thermospray MS in positive mode. An internal standard
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(deuterated DMZ) was employed to increase accuracy by compensating for losses during 
extraction. This method was used to investigate the effects of contamination levels of 
DMZ in feed on chickens and the possible occurrence of violative residues.
Cannavan et al. (1999) published an HPLC electrospray MS method for the determination 
of nicarbazin in animal feedingstuffs. This was followed by a method for the quantitative 
determination of 4,4-dinitrocarbanilide (DNC) the marker residue for the use of the drug 
in chicken liver and eggs. This method makes use of the MS-MS capabilities of the 
laboratory. After extraction, analysis was carried out using an isocratic mobile phase of 
0.05 mol f1 ammonium acetate in acetonitrile-water (75 : 25 v/v) on a Luna Qg column 
connected to a Micromass Quattro MS-MS spectrometer in negative mode (Yakkundi et 
a/., 2001).
MS-MS linked to HPLC gives enhanced sensitivity and selectivity to the methods and has 
recently allowed the development of a method for the confirmation of halofuginone, a 
prophylactic against coccidiosis used in commercial poultry production (Yakkundi et al., 
2003). This has led to the study of the pharmacokinetics of such residues in chicken liver 
and eggs due to contamination levels in feed (Yakkundi et al., 2002).
1.11. European Union legislation concerning LC-MS method validation
Before a method can be submitted for both internal and official regulatory approval, it 
must undergo systematic validation. The goal of validation is to determine the limits of 
variability for the method over the concentration range it is to be applied. Current criteria 
for method validation are covered by EU Commission Decision 2002/657/EC (European 
Commission, 2002). These contain specific validation details for LC-MS and MS-MS
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techniques and guidelines for the determination of method performance characteristics. 
The EU defines validation for LC-MS confirmatory methods in several parts: compound 
identification, recovery, repeatability, within laboratory reproducibility, reproducibility, 
the decision limit (CCa), and detection capability (CCP).
1.11.1. Compound identification
Criteria for chromatographic and analyte identification must be applied to confirm the 
presence of a specific compound when using a LC-MS method:
Chromatographic criteria
The minimum acceptable retention time for any analyte to be validated must be twice the 
void volume of the column. When no internal standard is available, the retention time of 
the analyte should closely match that of the same analyte in a corresponding standard. A 
margin of error of ± 5% of the retention time is allowed for this. The peak width at half the 
maximum height also should be within the 90-110% range of the original width.
When an internal standard is available the ratio of the retention time of the analyte to that 
of the standard must fall within predefined limits. EU legislation defined this as:
“The ratio of the chromatographic retention time of the analyte to that of the internal 
standard i.e. the relative retention time of the analyte, shall correspond to that of the 




All detected ions should be expressed as a percentage of the intensity of the most intense 
ion or transition product, known as the relative ion intensity. In all samples, ion intensities 
must correspond to those of the standards or spiked samples at comparable concentrations 
within predefined limits. These maximum permitted tolerances are outlined in Table 1.1.
Table 1.1. Maximum permitted tolerances for relative ion intensities using a range of mass 
spectrometric techniques.
Relative intensity






> 50 % ± 10% ± 20 %
> 20 % - 50 % ± 15% ± 25 %
> 10 % - 20 % ± 20 % ± 30 %
< 10% ± 50 % ± 50 %
(European Commission, 2002)
For confirmatory methods, a minimum of one relative ion intensity should be measured. A 
system of Identification Points (IP) is also awarded for each analyte ion identified based 
on the type of MS used. The number of points awarded per ion reflects the ability of an 
analyser to specifically select the analyte molecule or mass fragment e.g. tandem MS
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fragments will be awarded more IPs than single MS. The IP assignment system is outlined 
in Table 1.2.
Table 1.2. The relationship between a range of MS technique and Identification Points earned.
MS technique Identification points
earned per ion
Low resolution mass spectrometry (LR-MS) 1.0
LR-MS Precursor ion 1.0
LR-MS Transition products 1.5
High resolution mass spectrometry (HR-MS) 2.0
HR-MS Precursor ion 2.0
HR-MS Transition products 2.5
(European Commission, 2002)
Transition products can include both daughter and granddaughter products of the 
monitored precursor ion. Therefore methods using MS-MS will score 1.5 IPs for each ion 
measured, along with an additional 1 IP for the precursor ion whether it is measured or 
not. For substances having an anabolic effect and unauthorised substances (Group A of 
Annex I of Council Directive 96/23/EC), a minimum of 4 IPs are required for 
confirmatory methods. However, for veterinary drugs, including unlicensed substances 
used for veterinary purposes and contaminants (Group B of Annex I of Council Directive
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96/23/EC), only a minimum of 3 IPs are required. Up to three separate techniques may be 
used to achieve the minimum number of IPs required.
1.11.2. Recovery
Recovery is the percentage of the true concentration of a substance recovered during the 
analytical procedure. When there is no certified reference material available, recovery is 
assessed using fortified blank matrix samples. Six aliquots of blank matrix are fortified at 
each of 1, 1.5 and 2 times the Minimum Required Performance Limit (MRPL) for banned 
compounds or at 0.5, 1 and 2 times the MRL for legal compounds. From these the 
percentage recovery for each sample and mean recovery for each level of fortification can 
be calculated.
1.11.3. Repeatability
This is the degree of agreement among results at 1, 1.5 and 2 times the MRPL or at 0.5, 1 
and 2 times the MRL and can be assessed in the same analytical run as recovery. The 
mean concentration. Standard Deviation (SD), and Coefficient of Variation (CV) are 
calculated for each level of fortification.
1.11.4. Within-laboratory reproducibility
This is the degree of agreement among different sets of results when the procedure is 
repeatedly assessed at the same fortified concentration, over three separate runs, on 
separate days, to allow for different environmental conditions, analytical variations, 
operators, etc. This value is again is expressed as the mean concentration, SD and CV for 
each fortification level.
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1.11.5. Decision Limit (CCot)
EU legislation defines this for banned compounds and substances without a permitted 
residue limit as:
“The limit at and above which it can be concluded with an error probability of a that a 
sample is non-compliant.” (European Commission, 2002)
CCa, the decision limit, is the limit at which it can be decided that a sample is truly 
violative (greater than zero for an unauthorised substance) with an error probability of a. 
This study only involved compounds that have been banned within the EU, therefore a =
1%.
Y intercept plus 2.33 
times the standard 




Concentration added to 
known negative sampleY-axis intercept
CCa value
Fig. 1.1. CCa and Y intercept
Representative blank material should be fortified at below the MRPL (if assigned), 
analysed and the MS response versus fortified concentration plotted and the Y-axis 
intercept calculated. CCa is calculated from the graph as the concentration corresponding 
to 2.33 times the standard error of the Y intercept added to the Y intercept.
1.11.6 Detection Capability (CCP)
EU legislation defines this for banned compounds and substances without a permitted 
residue limit as:
“The smallest content of a substance that may be detected, identified and/or quantified in a 
sample with an error probability of p. In the case of substances for which no permitted 
limit has been established, the detection capability is the lowest concentration at which a 
method is able to detect truly contaminated samples with a statistical certainty of 1 - p.” 
(European Commission, 2002)
CCP, the detection capability, is the smallest content of analyte that may be detected, 
identified, and quantified in a sample with an error probability of p. In the case of 
unauthorised substances, the P error should be less than or equal to 5%. The CCP can be 
extrapolated graphically through the addition of 1.64 times the standard error of the Y 
intercept to the Y value for mean measured content at the decision limit (CCa).
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Fig. 1.2. CCa and CCp graph
1.12. Quinoxaline-N-dioxides
The quinoxaline-N-dioxides are yellow crystalline solids with melting points > 200 °C and 
their solubility in water and other organic solvents is dependent on the side chain present. 
They were first prepared as a potential (and undemonstrated) antagonist to vitamin K 
activity and later discovered to have antimicrobial properties. Quinoxaline-N-dioxides are 
classed as ‘other antibacterial drugs’ due to their structure, which does not easily fit into 
any of the major classes of antibacterial agents. Structurally they are derivatives of the 
quinoxaline ring system. Introduction of different sidechains (-R) on the 2nd and 3rd carbon 
in the quinoxaline-N^N^dioxide ring gives rise to a small number of compounds which 
all exhibit anti-bacterial and coccidiostatic properties (see Fig. 1.3.). A few of these 
compounds have additionally exhibited growth-promoting effects if used as an infeed 
additive, several already having been used within the livestock industry. Quindoxin 
(QDN) was added at 50 mg kg"1 infeed as a growth promotant in young chickens within
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the poultry industry (Broome and Bowie, 1972). Carbadox (CBX) and Olaquindox (OQX) 
were used as prophylactic agents and growth promotants in young pigs at concentrations 






Fig. 1.3 Structures of QDN and its derivatives, CBX, OQX and cyadox.
1.13. Carbadox
1.13.1. Chemistry and physical properties
CBX, methyl-3-(2-quinoxalinyl-methylene)carbazate-Nl,N4-dioxide or
2-formylquinoxaline-1,4-dioxide carbomethoxyhydrazone, has a molecular formula of
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C11H10N4O4 and a molecular weight of 262.23 (see Fig. 1.4.), and has a melting point of
239.5 - 240 °C.
Fig. 1.4. Chemical structure of CBX.
1.13.2. Absorption, metabolism and pharmacokinetics
Shortly after the start of oral administration (3-5 hours) of CBX, several metabolites have 
been identified in plasma: CBX, desoxycarbadox (desoxy-CBX), carbadoxaldehyde, and 
Quinoxaline-2-Carboxylic Acid (QCA). After 24 hours another metabolite - 
methylcarbazate was identified in plasma along with trace amounts of hydrazine 
(WHO/FAO, 1991). Upon withdrawal of medication, CBX metabolites have been reported 
to disappear rapidly from serum and blood within 48 to 72 hours. Disappearance from 
tissues such as muscle, liver and kidney is seen on a similar time scale, with the desoxy- 
CBX metabolite persisting for slightly longer (Macintosh et al., 1985). Twenty four hours 
after the withdrawal of medication, the major detectable residue is QCA along with only 
small amounts of methylcarbazate, CBX and desoxy-CBX (Lauridsen et al., 1988). The 
enzymes involved in CBX catabolism have not yet been elucidated. Once CBX and 
desoxy-CBX are converted to QCA no further metabolism of the drug occurs (see Fig. 
1.5.).
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Hydrazine + Nj + COj + NH3
Fig. 1.5. Simplified pathway for the breakdown of CBX.
The majority of residues are removed from the system within 72 hours of medication. The 
major pathway for excretion is via the urine (60-70%) with lesser amounts (10-20%) in 
faecal matter carried by bile (WHO/FAO, 1991). The QCA metabolite may be present in 
tissues for extended periods of time, with the exception of muscle where elimination 
occurs within the normal 72 hours (Baars et ai, 1990). Using pigs given rations medicated 
at 20 mg kg'1, which is less than half the prior recommended prophylactic level, QCA
-42-
residues were present in liver samples 30 days after the cessation of treatment (Lauridsen 
et ai, 1988). Another study using the recommended prophylactic concentration 
(50 mg kg'1) found that QCA residues were still detectable in liver, 77 days after the 
cessation of treatment (Rutalj et ai, 1996).
1.13.3. Growth promoting action
CBX and other QDN derivatives have been shown to be effective growth promotants for 
young pigs by administration in feed (Thrasher et al., 1969). Significantly increasing the 
weight gains, feed efficiency and reducing the rearing period for young pigs even on 
protein poor diets (Bourdon et al., 1977). Early in the use of antimicrobials, the mode of 
action of growth promotion was thought to be related to effects on gastrointestinal 
microflora (Visck, 1978). Even today, this mode of action is speculative, the theory based 
on the suppression of catabolism of urea and amino acids and decreased carbohydrate 
fermentation by the action of the antibacterial agent on gut flora. This leads to the 
increased availability of nutrients and amino acids to the animal host. Initially this was 
suspected of CBX (Gedek, 1979). However, in pigs fed twice the recommended 
prophylactic dose (100 mg kg'1) severe adrenocortical damage and an enlarged glomerular 
zone was discovered upon autopsy (Van der Molan et al., 1985). Hypoaldosteronsium i.e. 
a reduction in aldosterone production resulting in the loss of sodium and potassium 
resulting in hypotension, was also reported with CBX use in vitro (Spierenburg et al., 
1988b) and in vivo (Van der Molan et al., 1986). Hence, CBX seems to have very specific 
effects on adrenal tissue in pigs. This has led to the discovery that CBX has anti-catabolic 
effects through reduced secretion of cortisol, corticosterone, aldosterone and deoxycortisol 
in vitro and in vivo by porcine adrenocortical cells (Jager et al., 1996). In addition to a 
reduction in the cortisol-derived hormones, CBX increases the rate of secretion of
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progesterone. This implies that CBX irreversibly or non-competitively inhibits the 
2ip-hydroxylase enzyme responsible for the conversion of progesterone to 
deoxycorticosterone and 17-OH-progesterone to deoxycortisol (see Fig. 1.6.). These are 
steps in the major metabolic pathways for the production of aldosterone and cortisol (Jager 
et al., 1996).
Progesterone is a precursor in the anabolic pathway for the testosterone, and increased 
secretion of progesterone will lead to increased secretion and plasma levels of 
testosterone. Testosterone is known to have many anabolic effects and in conjunction with 
a high protein food intake (such as in pig rations) will give a positive nitrogen balance in 
the body through the increased uptake and retention of dietary nitrogen. This ultimately 
leads to amplified muscle and adipose tissue formation. This is supported by CBX being 
noted as having a marked effect on the uptake and retention of dietary nitrogen (Yen et al., 
1976).
CBX is rapidly metabolised to desoxy-CBX that has been found to have identical 
inhibitory effects (Jager et al., 1996). Consequently, though CBX has a direct anabolic 
effect, it also acts as a pro-drug extending the therapeutically active time through its 
metabolite. CBX does not overly affect the secretion of the other major anabolic hormones 
- progesterone, HO-progesterone, androstenedione or dehydro-epi-androsterone (Jager et 
al., 1996). Normal serum levels of each will have enhanced effects as secretion of the 
opposing negative feedback catabolic hormones is reduced. CBX has also been shown to 
inhibit the 7a-hydroxylase enzyme for the conversion of cholesterol to 7a- 
hydroxycholesterol, the first step in the catabolism of steroids and the production of the 











Fig. 1.6. CBX inhibition points in the major metabolic pathways for the biosynthesis of
adrenocorticosteriods.
This will lead to increased steroid production (and ultimately progesterone secretion, 
through the previously mentioned inhibited enzymes), as more precursor molecules are 
available - again enhancing the effect of CBX on the anabolic system. Steady state kinetic 
studies with CBX in weaned piglets feed medicated feed (50 mg kg'1) over 90 days 
showed CBX to maintain steady concentrations in porcine blood between 10 - 50 ng ml"1 
(De Graaf et al., 1988). With the daily administration of medication, continuous anabolic
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effects are exerted on the porcine system. Such effects will persist for some time after the 
cessation of treatment, as time is required to reverse the inhibition of aldosterone 
production.
1.13.4. Veterinary use and clinical symptoms
Though primary use has been as a growth promoter in both piglets (Jost, 1979) and broiler 
chickens (Schuler et al., 1977), CBX also has a clinical function with antimicrobial effects 
on gram-negative bacteria. Combined with pryantel tartrate in feeds it acted as a strong 
prophylactic against swine kidneyworm (Stewart et al, 1979) and was used in the 
treatment of infectious atrophic rhinitis (Farrington and Shively, 1978). Action in the 
prevention of enteric colibacillosis (Pujin et al., 1974) and reduction in the severity of 
salmonellosis (Troutt et al., 1974) were also reported. The main clinical use of CBX was 
as a prophylactic antitreponemal agent. Use of CBX medicated feed (50 mg kg"1) 
prevented the clinical signs of swine dysentery (haemorrhagic enteritis), a disease 
commonly found in the pig industry (Williams and Shively, 1978). Prevention was 
through bacteriostatic action on the growth of Treponema hydysenteriae (Williams and 
Babcock, 1976), the primary pathogen in swine dysentery (Hughes, 1975). 
Pharmacokinetic studies have shown that the concentrations of CBX in the gastrointestinal 
tract after medication (50 mg kg"1) are high enough to have a bacteriostatic action. 
Consequently oral dosing was an effective prophylactic treatment against invading 
treponemes (De Graaf et al., 1988).
Feed concentrations of 100 - 150 mg kg"1 have also been used as a direct treatment for 
Treponema hydysenteriae infection. Conversely at such elevated medication levels CBX 
use causes decreased secretion of aldosterone, leading to induced hypoaldosteronism in
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severe cases (Van der Molen et al., 1989b) - questioning its efficiency as a direct 
treatment, but not as a prophylactic. Extended use (>5-7 days) at such concentrations (100 
- 150 mg kg'1), can become detrimental to animal health. Induced symptoms include 
dehydration, reluctance to eat, loss of condition, posterior paresis, greatly increased heart 
rate, decreased appetite, wall licking, urine drinking and an appetite for salt, the passing of 
hard faecal matter and ultimately death (Nabuurs and Van der Molan, 1989; Van der 
Molan, 1988). Such clinical symptoms can be attributed to the secondary effects of CBX 
on the renin-angiotensin system (RAS) and by the inhibition of bile acid synthesis.
The inability to produce aldosterone in turn leads to hypoatraemia and hyperalaemia and a 
decreased plasma ratio of sodium to potassium - giving a negative water balance, 
decreased plasma volume, an increased heart rate and dehydration (Power et al., 1989). 
Through the negative feedback mechanism between the RAS and aldosterone plasma 
levels, decreased aldosterone production causes the rise of plasma angiotensin II levels 
(Van der Molan et al., 1989a) to trigger its production and secretion from the adrenal 
glomerulosa. Pigs with CBX intoxication have been reported to show clinical symptoms 
such as depraved appetite, wall licking, urine drinking (appetite for salt) even after 
medication has ceased and aldosterone levels have returned to normal (Nabuurs and Van 
der Molan, 1989). These might be explained by the continual increased RAS activation 
through angiotensin II, which has been shown responsible for salt appetite. CBX has been 
reported to inhibit the 7a-hydroxylase enzyme in the metabolism pathway of cholesterol 
to 7a-hydroxycholesterol (Tracy and Jensen, 1987). This is a rate limiting enzyme for the 
biosynthesis of the bile acids (lithocholic acid, chenodexoycholic acid, and 
hydrodeoxycholic acid) in pigs. Continual elevated levels of CBX in the blood will
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severely impede the production of bile acids and therefore greatly reduce biliary secretion 
into the gastrointestinal tract via the bile duct, leading to the passing of hard faecal matter.
1.13.5. Mutagenic properties and antibacterial activity
Since the introduction of CBX as an antimicrobial agent, many studies have shown that it 
also exhibited mutagenic properties. Other coccidiostatic agents such as dimetridazole and 
ronidazole have been shown to increase the mutation rate in Klebsiella pneumoniae, 
Escherichia coli and Citrobacter freundii using fluctuation assays (Voogh et al., 1974). 
Such suspicions led to the investigation of the possible mutagenic properties of CBX. 
Early in its use as a growth promoter CBX was shown to cause in vitro chromatid 
aberrations in bone marrow cells and increased micronucleated polychromatic 
erythrocytes - an indicator of bone cell genetic aberrations (Oud et al., 1979). In vitro 
mutagenic changes were also reported with Bacillus subtilis and Salmonella typhimurium 
(Yoshimura et al., 1981). CBX has been shown as mutagenic at very low concentrations 
(2.0 - 500 x 10mM). Using the Ames test with Salmonella spp. such action has been 
demonstrated to be without metabolic activation (Voogh et al., 1980) i.e. the compound 
itself is the mutagen.
With in vitro mutagenic activity demonstrated, establishing the effect of the drug in vivo in 
mammals was of importance as personnel within the agricultural industry would be at risk 
of exposure. CBX use in vivo increased the number of micronucleated polychromatic 
erythrocytes in rats (Cihak et al., 1983) and demonstrated aberrant effects in the foetal 
liver of pregnant mice (Cihak and Vontorkova, 1985). Short-term teratogenic and 
embyrolethal effects have been confirmed in utero in rats (Yoshimura, 2002). The above
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studies show that CBX is mutagenic and carcinogenic in vitro and carcinogenic, genotoxic 
and embyrolethal in vivo.
Positive results have been published for CBX using the rec test that assays UV-induced- 
like damage and single strand breaks in cellular DNA (Yoshimura et al., 1981). Hence, 
CBX directly attacks bacterial DNA, leading to errors in the DNA template and causing 
both base-pair substitutions and frame-shift mutations because of errors in the DNA repair 
process. This will subsequently inhibit the synthesis of DNA i.e. a bacteriostatic effect. 
Such conclusions are supported by reports that DNA repair enzyme deficient spp. are 
more susceptible to CBX and other quinoxaline-N-dioxides (Beutin et al., 1981; Suter et 
al, 1978).
The endogenous mutagenicity of the parent compound and ring metabolites has been 
demonstrated to be linked to the presence of the N-oxide groups of the quinoxaline ring, as 
quinoxaline-N-oxide exhibits lower mutagenic properties than the N,N-dioxide form 
(Beutin et al., 1981). The reduced metabolite desoxy-CBX has also been shown to be a 
potent hepatocarcinogen and tumour inducing agent in vivo in rats and mutagenic in cell 
tests in vitro (WHO/FAO, 1991), however the mechanism of this action is currently 
unknown. During metabolism of desoxy-CBX the side chain attached to the 2nd carbon of 
the quinoxaline ring is cleaved off, giving a methylcarbazate group that can be further 
broken down to hydrazine. Many unrelated studies with hydrazine have shown that it is a 
genotoxin and tumour-inducing agent both in vitro and in vivo (WHO/FAO, 1991). 
Hydrazine is a minor metabolite and would only be expected to be present in vivo for a 
short period; whether such trace levels will have any mutagenic effect has yet to be
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clarified. Only the QCA metabolite has been shown not to exhibit any mutagenic 
properties (Yoshimura et al., 1981).
The antibacterial activity and the mutagenicity of quinoxaline-N-oxides are suspected of 
being linked. Both activities are enhanced under anaerobic conditions, suggesting that 
each are due to the same activation mechanism (Beutin et al., 1981) i.e. the reduction, 
alteration or aberration of DNA through the N-oxide groups on the quinoxaline ring. This 
has been supported by cyclic voltammetry data, which suggests that some relationship 
exists between the reduction potential of the compounds and their antimicrobial activity 
(Crawford et al., 1986).
1.13.6. European Union legislation concerning carbadox
CBX was first listed as a zootechnical feed additive under Part E (other additives) of the 
Annexes to EU Council Directive 70/524/EEC in 1974 by Council Directive 74/378/EEC. 
EU authorisation was granted for its use as a feed additive in pigs in 1987 at medication 
concentrations of 50 mg kg'1 by the amendment and addition of CBX to Annex I of the 
same Council Directive (European Commission, 1987a). The conditions of its use were 
further amended in 1990 (European Commission, 1990c) and 1996 (European 
Commission, 1996a). Authorisation was granted in 1987 despite worldwide reports in 
1972, 1984 and 1985 that CBX and desoxy-CBX were suspected carcinogens and 
mutagens.
During the 1980s and early 90s when CBX was available as a pre-mix formulation under 
licence in the EU, several reports were published that CBX caused genotoxicity both in 
vitro and in vivo. Desoxy-CBX and the side-chain metabolite methyl carbazate (that can
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be further metabolised to generate hydrazine) were also suspected carcinogenic and 
tumour inducing agents (see Section 1.13.5.)- The Federal Republic of Germany requested 
on 14th February, 1997, a re-evaluation of quinoxaline-N-dioxides, due to concerns over 
possible risks to consumers, operators and animals. Both SCAN and the European 
Commission acknowledged that CBX was carcinogenic and genotoxic in rodents, though 
SCAN noted that quinoxaline-N-dioxides were acceptable for use under their previously 
defined conditions (SCAN, 1998). The European Commission believed that it was not 
possible to set a threshold limit for a genotoxic agent, when even small quantities can 
induce tumour-initiating mutations, consequently not allowing withdrawal times to be set. 
CBX was withdrawn from use in the EU on lsl January, 1999, under Commission 
Regulation No 2788/98 (European Commission, 1998), over these mutagenic concerns 
and the unacceptable risks it posed to the consumers, and industry and farmer workers. 
CBX was freely available in the Republic of Ireland up until the 1st September 1999 
(though it had not been available in the UK since the mid. 1980s). It is still available as a 
medicated feed product in the USA, Canada and the rest of the world under licence. CBX 
does not come under EU Council Directive No 2377/90, as it is not considered a 
veterinary medicine and was only ever licensed as a zootechnical feed additive. Therefore, 
it has been removed from Annex B of EU Council Directive 70/524/EEC that governs the 
use of zootechnical feed additives, but not added by amendment to Annex IV of EU 
Council Directive No 2377/90. The current EU prohibition on CBX use is enforced under 
the UK National Surveillance Scheme by monitoring for the presence of the marker 
residue, QCA, in livestock at slaughter.
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1.13.7. QuinoxaIine-2-carboxyIic acid
Quinoxaline-2-carboxylic acid, which has the molecular formula C9H6N2O2, has a m.w. of 
174.158 and is soluble in alcohols and slightly soluble in water. It is a quinoxaline ring 
with a carboxylic acid group attached to the 2nd carbon of the ring (see Fig. 1.7.). Unlike 




Fig. 1,7. Chemical structure of QCA.
QCA has been assigned as the marker residue for CBX, as it is deemed the most persistent 
measurable metabolite through metabolism and depletion studies (Ferrando et al., 1975). 
The target tissue of this metabolite is the liver in which the presence of QCA residues have 
still been detected after 6 weeks (Rutalj et al., 1996). Unlike its precursors (CBX, desoxy- 
CBX and monoxy-CBX) QCA has been shown not to be mutagenic, carcinogenic, or 
cause developmental, embryo, or maternal toxicity in vivo (WHO/FAO, 1990; Yoshimura 
et al., 1981). Through the withdrawal of CBX from Annex B of EU Council Directive 
70/524/EEC that governs the use of zootechnical feed additives, the use of CBX is 
prohibited in the EU from 1st September, 1999. Before the withdrawal of this licence, the 
MRL for QCA was set at 30 pg kg'1 in liver samples. Now that CBX is listed in the 
banned compounds to be analysed for under the UK National Surveillance Scheme, the 
presence of any detectable concentration of QCA above the stated Limit Of Quantification
-52-
(LoQ) of the assay in a tissue submitted for testing is considered indicative of misuse. 
Such a positive laboratory test can lead to further sampling of the producer and 
prosecution if confirmed.
1.14. Olaquindox
1.14.1. Chemistry and physical properties
OQX, 2-(N-2-hydroxyethylcarbamoyl)-3-methyl-quinoxaline-N1 ,N4-dioxide or 
N-(2-Hydroxyethyl)-3-methyl-2-quinoxalinecarboxamide-1,4-dioxide, has the molecular 
formula C12H13N3O4 with a m.w. of 263.25 (see Fig. 1.8.), and has a melting point of 209 
°C.
1.14.2. Absorption, metabolism and pharmacokinetics
After a single oral dose (50 mg kg'1), OQX is rapidly absorbed and has been measured in 
plasma, muscle, liver and kidney of chickens after only 25 minutes (Li et al., 1995). After 
2 hours OQX and two mono-A-oxides could be identified in plasma (WHO/FAO, 1995). 
Tissue and plasma concentrations are highest at this time and rapidly decline through
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either metabolism or excretion with negligible quantities present after 24 hours (Li et al., 
1995). Differences have been found when measuring the levels of OQX and its reduction 
products in serum and whole blood. This indicates that a portion of OQX and its 
metabolites binds to corpuscular blood constituents (Fink and Kreisner, 1982), rather than 
being completely free in the plasma. The majority (~70%) of OQX is excreted unchanged 
in the urine. Metabolites are also present following limited biotransformation in the liver 
and kidney (see Fig. 1.9.). The foremost metabolites, resulting from omega oxidation are 
monoxyolaquindox (monoxy-OQX) and desoxyolaquindox (desoxy-OQX), though several 
others have been identified (WHO/FAO, 1991; WHO/FAO, 1995). The major detectable 
residue present in tissue after 24 hours is methyl-3-quinoxaline-2-carboxylic acid 
(MQCA), with only small or negligible concentrations of the other metabolites present. 
Residue studies have shown that the depletion of such MQCA from tissues is linear over a 
20 day period (WHO/FAO, 1995).
Speirenburg et al. (1988a), using pigs given OQX medicated rations (58 mg kg"1), found 
that concentrations of drug were highest in the stomach with a steady decline along the 
gastrointestinal tract. Concentrations dropped below the detection limit in the colon 
suggesting that OQX is continuously absorbed throughout the gastrointestinal tract. Like 
other quinoxaline-N-dioxides, OQX can be reduced to its corresponding monoxy and 
desoxy derivatives in the gastrointestinal tract by endogenous enzymes and bacteria (Suter 
et al, 1978). This opens the possibility that absorption is not complete and that reduction 
accounts for a portion of the decline in OQX content throughout the gastrointestinal tract, 













MQCA Side chain metabolites
Fig. 1.9. Simplified metabolism pathway of OQX.
1.14.3. Growth promoting action
OQX has been shown to increase significantly the daily weight gains and feed conversion 
efficiency in young pigs when administered as a feed additive (100 mg kg'1) in 
comparison to an unmedicated (control) group (Pfirter et al., 1978). One group of 60 
piglets was fed OQX at infeed concentrations of 50 mg kg'1 over a 28-day period. They
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demonstrated a 77.9% increase in weight gain and a 29.3% increased feed utilisation 
compared to piglets fed identical unmedicated rations over the same time period. In a 
similar number of piglets fed CBX infeed (50 mg kg'1), little difference was seen in the 
weight gains and feed utilisation effects in comparison to OQX (Broz et al., 1978). OQX 
is also reported to affect the release and production of aldosterone in adrenocortical tissue 
in vitro (Jager et al., 1994; Van der Molen et al., 1989b), though the effect of the 
N-reduced metabolite desoxy-OQX has not been described. OQX, being a 
quinoxaline-N-dioxide like CBX - with similar growth promoting and aldosterone 
secretion effects - could be hypothesised to have a mode of growth promoting action 
similar of CBX, i.e. affecting the secretion of steroid hormones (see Section 1.13.3.). 
However, whether OQX and/or desoxy-OQX inhibit the same or different enzymes in the 
neogenesis pathway for aldosterone and cortisol has not been elucidated. Studies reporting 
increases in weight gain, feed efficiency and nitrogen retention etc. similar to CBX imply 
that it is likely the same Cig-hydroxysteriod deydrogenase and/or 21 p-hydroxylase 
enzymes that are affected.
1.14.4. Veterinary use and clinical symptoms
Like other quinoxaline-N-dioxides, OQX has an antimicrobial action against gram­
negative bacteria and also acts as antitreponemal agent, (Williams and Shively, 1978) 
through bacteriostatic action on the growth of Treponema hydysenteriae (Williams and 
Babcock, 1976) - the cause of swine dysentery. Pharmacokinetics studies in pigs have 
shown that OQX concentrations are highest in the stomach and decline steadily along the 
gastrointestinal tract. These concentrations, when compared to the MIC for Treponema 
spp., show that continuous medication at approximately 100 mg kg'1 per day would be 
necessary for a prophylactic effect (Speirenburg et al., 1988a). However, doses slightly
-56-
above 100 mg kg'1 have been shown to have a high risk of serious side effects to the 
animal. Consequently, the therapeutic window for OQX use as a prophylactic is small and 
the risk of accidental overdose is high. In cases of OQX overdose, clinical symptoms 
reported appear similar to that of CBX. A markedly decreased plasma sodium to 
potassium ratio, dehydration, reluctance to eat, posterior paralysis, hard faecal matter, 
damage of the zona glomerulosa in the kidney and increased adrenal capsule volume 
(Newsholme et al., 1986). These symptoms could be hypothesised to be caused by 
continuous elevation of aldosterone production and the subsequent secondary effects on 
the RAS as found with CBX overdose (see Section 1.13.4.). This is supported by studies 
showing dose-dependent decreases in aldosterone production, hypoatraemia, 
hypochloraemia, hyperalaemia and hydropic degeneration of the adrenal cortex in piglets 
fed OQX medicated rations (WHO/FAO, 1991).
1.14.5. Mutagenic properties and antibacterial activity
Though OQX shows mutagenic character, it shows less reactivity than CBX. For example, 
CBX is mutagenic at 0.001 M in agar with Salmonella typhimurium, whereas OQX is 
mutagenic at 0.02 M under the same conditions (Voogh et al., 1980). Thus, though OQX 
can induce base-pair substitutions and frame shift mutations, approximately 20 times the 
amount is required to have the same mutagenic effect in vitro. (Beutin et al., 1981; 
Nunoshiba and Nishioka, 1989).
Mammalian studies with OQX have shown similar mutagenic effects as CBX. OQX has 
been demonstrated to cause in vivo cytogenic damage in the foetal liver of pregnant mice 
(Cihak and Vontorkova, 1985) and induce micronucleated polychromatic erythrocytes in 
rats (Cihak et al., 1983). The genotoxicity of OQX in the mammalian system has been
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demonstrated in vivo with chromosomal aberrations and gaps reported in the bone marrow 
cells of mice (Cihak and Vontorkova, 1983). Positive results for OQX using the rec and 
uvr assays demonstrate that the bacterial DNA is damaged by UV-induced-like dimers and 
not just single strand breaks (Yoshimura et al., 1981). Consequently, OQX must directly 
attack bacterial DNA interfering with the DNA repair process and therefore is genotoxic.
The mutagenicity of the quinoxaline-N,N-dioxides and their ring metabolites has been 
demonstrated to be dependent on the presence of the N-oxide groups substituted for 
carbon on the 1st and 4th positions of the quinoxaline ring. Partially reduced quinoxaline- 
N-oxide exhibits lower mutagenic properties than the N,N-dioxide form and fully reduced 
derivatives do not show any mutagenic properties (Beutin et al., 1981). Thus, monoxy and 
desoxy metabolites of OQX are suspected mutagens and thought to possess carcinogenic 
properties. OQX’s genotoxic potential and antibacterial activities are also suspected of 
being linked to the ability of the drug, through the N',N4-dioxide groups, to cause base- 
pair substitutions and frameshift mutations in gram-negative bacterial DNA encountered 
in the gastrointestinal tract. Such conjectures have still to be proved.
1.14.6. Phototoxicity
Drug molecules can induce skin reactions similar to sunburn and edema. These are 
comparable to allergic contact reactions, with the UVA induced photoproduct of the 
compound usually being the sensitising agent. This may occur after physical contact with 
the drug or following medication. Such photoproducts are usually formed in the upper 
dermal layers of the skin, and can specifically or indiscriminately react with cellular 
structures and constituents causing an inflammatory reaction. The largest proportion of 
such damage will occur in situ to its formation. However, it may also be found in other
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organs and tissues if elevated concentrations are produced in proximity to the 
bloodstream.
OQX is a derivative of QDN, which was withdrawn from use after reports of photocontact 
dermatitis in stockmen who were exposed to it during the course of their work. The 
phototoxicity of this compound is acute and has caused both transient and persistent light 
reactions lasting over four years in some reported cases (Zaynoun et al., 1976). It is not 
surprising that OQX has been reported to show similar photoallergic properties. 
Francalanci et al. (1986) reported a possible case of OQX photosensitivity in a pig farm 
worker employed in the preparation and distribution of OQX medicated feed. Red scaly 
lesions were present on light exposed parts of the body such as the back and sides of the 
neck and the dorsa of the hands. A positive photopatch test confirmed that this was a 
photoreaction to OQX. Further cases of photoallergy after exposure were reported in the 
1980s and 1990s. These again showed lichenification of the head, neck and hands upon 
exposure to sunlight, with the symptoms lasting for considerable lengths of time after the 
initial onset of the photoallergy (Bedello et al., 1985; Dunkel et al., 1990; Kumar and 
Freeman, 1996). All safety data sheets for the handling of OQX recommend that contact 
with OQX or OQX containing products should be avoided, and the photoallergic effects 
can be attributed to a disregard of such guidelines in some of the cases. A small 
percentage of the cases have been attributed to sensitisation via airborne particles, through 
the dust generated by mixing or handling of mealy OQX medicated feeds. This has been 
reported to induce airborne photoallergic contact dermatitis on exposed parts of the body 
in “sensitive” individuals (Schauder et al., 1996). The mechanism by which OQX induced 
photosensitivity was elucidated in the early 1990s. The HPLC analysis of the urine of rats 
fed OQX (60 mg kg'1) over four days, showed a significant decrease in the observed
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amount of OQX excreted between animals exposed to UV light and those kept in the dark 
(De Vries et al., 1990). A profound change in the metabolism of OQX is thought to occur, 
with the formation of an oxaziridine derivative through the reaction of OQX with UV light 
in the dermis. This reaction type is also seen with other photoallergy inducing agents such 
as chlorpromazine. Such derivatives are highly reactive and can damage proteins, 
membranes, and other cellular constituents near to their formation leading to such dermal 
effects being observed. Glutathione (GSSG) is thought to reduce the OQX oxaziridine 
derivative (as also seen in oxaziridine formation in other imino-N-oxides) to OQX-4- 
monoxide (see Fig. 1.10.). This is supported by the detection of significant amounts of 
OQX-4-monoxide in the urine of UV exposed rats (De Vries et al., 1990). In normal OQX 
metabolism this metabolite is only present in urine in small concentrations, the majority 




Fig. 1.10. Reaction of OQX with UV light and the formation of OQX-4-monoxide.
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1.14.7. EU legislation concerning OQX
OQX was first listed as a zootechnical feed additive under Part F of the Annexes to EU 
Council Directive 70/524/EEC in 1976 by EU Council Directive 76/933/EEC (European 
Commission, 1976). EU authorisation for the conditions of its use was also granted in the 
same year at feed concentrations of 50 mg kg'1 (European Commission, 1987b).
In the 1980s and 1990s, several published papers reported both photoallergic and 
photosensitive effects of OQX in humans (see Section 1.14.6.). This culminated in a report 
published in November 1992 implicating OQX in cases of photoallergic contact dermatitis 
in pig producers and farm workers. Other reports published at the same time reported the 
in vitro and in vivo genotoxic and germ cell mutagenic properties of OQX and its 
metabolites (see Section 1.14.5.).
On 14th February, 1997, the Federal Republic of Germany requested a re-evaluation of all 
quinoxaline-N-dioxides, over concerns of possible risks to the consumer, operators and 
pigs. After further studies, OQX was classified as a genotoxic agent and possible germ 
cell-line mutagen, in addition to being a direct danger to both feed factory workers and 
swine producers through its photoallergic properties. The EU decided to withdraw OQX 
from use along with CBX on 31s' August, 1998 (European Commission, 1998). OQX 
medicated feed was freely available in the Republic of Ireland up until 1st September, 
1998, though not within the UK. It is still legally produced under licence as premixed feed 
in the USA, Canada and other parts of the world. OQX does not come under EU Council 
Regulation No 2377/90, as it was never classified as a veterinary medicine but rather a 
zootechnical feed additive. Therefore, it has been removed from Annex B of EU Council 
Directive 70/524/EEC, but not added to Annex IV of EU Council Regulation No 2377/90
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through separate legislation. The current EU prohibition on OQX use should be enforced 
by the monitoring for the presence of the marker residue, MQCA, in livestock at slaughter.
1.14.8. Methyl quinoxaline carboxylic acid
MQCA, which has the molecular formula C10H9N2O2, has a m.w of 189.193 and is soluble 
in alcohols and slightly soluble in water. It is a quinoxaline ring with a carboxylic acid 
group attached to the 2nd carbon of the ring and a methyl group attached to the 3rd carbon 
of the ring (see Fig 1.11.). Like QCA, it has no N-dioxide groups.
O
Fig. 1.11. Chemical structure of MQCA.
OQX is extensively metabolised in pigs and the concentration of metabolites has been 
found to vary notably between different tissue types and animal species. MQCA was 
found to be the longest remaining tissue metabolite, in vivo after OQX medication. As 
MQCA tissue depletion is linear over time, MQCA has been assigned as the marker 
residue for OQX use by the FAO and WHO (WHO/FAO, 1995). The mutagenic effects of 
the quinoxaline-N-dioxides have been attributed to the reduction ability of N-oxide groups 
present on the ring structure. The toxicity/mutagenicity of MQCA is not yet known, 
however, MQCA is unlikely to exhibit such properties, as no N-oxide groups are present. 
The structure of MQCA differs only from that of QCA by a methyl group on the 3 rd 
carbon of the quinoxaline ring. QCA has been shown not to be mutagenic, carcinogenic.
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embryo lethal or a developmental antagonist (see Section 1.13.5.). Consequently, it may 
be suggested that MQCA is also unlikely to exhibit such effects.
The use of OQX was prohibited in the EU as from 1st September, 1999. No MRL or 
MRPL for MQCA has ever been set; therefore, any detected concentration of MQCA in a 
sample above the LoQ of the assay is indicative of OQX use. Such a positive result could 
lead to further sampling of the producer by the regulatory authorities and subsequent 
prosecution in a court of law. However, OQX is not currently monitored by UK statutory 
or non-statutory National Surveillance Schemes and implementation of a standard residue 
test is still to be carried out in many EU countries.
1.15. Analytical methods
1.15.1. Detection of carbadox in feedingstuffs and tissue
In the 1970s detection methods for CBX were largely concerned with the analysis of feed 
(Goras, 1979; Luchtefeld, 1977; Thorpe, 1976; Thorpe, 1978). This involved the 
extraction of the drug from the matrix by a solvent followed by a form of column 
chromatography and then UV/Vis detection. For example, Goras et al. (1974) extracted 
CBX from the matrix with chloroform-methanol solution (3 : 1 v/v), followed by solvent- 
solvent extraction using potassium phosphate solution (1 M). The sample was applied to 
an activated alumina column prepared with dimethylformamide (DMF), with CBX 
forming a yellow band on the column. This was eluted with further volumes of 
chloroform-methanol solution (3 : 1 v/v). The organic eluate was then back extracted in 
sodium hydroxide solution (0.1 M). In sodium hydroxide solution, CBX formed a strong 
chromophore that could be measured against a standard at 420 nm.
-63-
Such methods were slow and laborious, but with the development and routine application 
of HPLC in the 1980s allowing faster analysis times, this increasingly became the 
separation method of choice. In the 1980s many of these feed methods were based on a 
simple sample clean-up followed by HPLC with UV detection (Aerts and Werdmuller, 
1987; De Graaf and Spierenburg, 1985; Roybal et al., 1985). Lowie et al. (1983) used a 
methanol-acetonitrile solution (50 : 50 v/v) extraction to remove both CBX and pyrantel 
tartrate from feed. This was followed by alumina column clean up, HPLC and analysis at 
365 nm for CBX and 313 nm for pyrantel tartrate. HPLC linked to spectrometric detection 
could be tailored to allow the detection of one or several other drugs. Several methods 
have been reported that include CBX (Dos Ramos et al., 1991; McGary, 1986), one 
method by Thorpe (1980), measured CBX, furazolidone, nitrofurazone and ethopabate all 
within the same sample.
Fluorescence detection linked to HPLC has been published for CBX and desoxy-CBX in 
both medicated feed and the contents of the gastrointestinal tract (De Graaf and 
Spierenburg, 1985). Samples were extracted with a DMF-water solution (95 : 5 v/v) and 
cleaned up using either gradient elution for the simultaneous assay of both compounds or 
isocratic elution for the assay of CBX only. Detection of CBX by its native fluorescence 
(excitation at 310 nm and emission at 487 nm) yielded a sensitive and specific assay 
allowing greater specificity in the quantification of CBX compared to UV/Vis detection 
alone.
In the 1980s due to concerns over the mutagenic properties of CBX and related 
metabolites, development of tissue detection methods became a priority. For example 
Aerts et al. (1988) reported an HPLC method for the pharmacokinetic detection of both
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CBX and the monoxy and desoxy metabolites in tissues. A simple liquid-liquid extraction 
followed by an alumina-florsil cleanup and subsequent iso-octane partitioning was used to 
prepare the sample. HPLC was used with the post-column addition of an alkali to give a 
yellow chromophore that can be measured at 420 nm. The method allowed detection at 1.0 
pg kg'1 and 5 pg kg'1 for CBX/monoxy-CBX and desoxy-CBX, respectively. This method 
was further optimised and extended to include other tissue types such as plasma and eggs 
(Binnendijk et ah, 1991). HPLC methods for the detection of CBX in other tissues such as 
swine muscle and kidney have also been reported (Aerts et al., 1988; Nagata and Saeki, 
1991).
Recently HPLC linked to mass spectrometry instead of UV or fluorescence detection has 
allowed the determination of CBX and 12 other antibacterial reagents (OQX, 
trimethoprim, clopidol, ormethoprim, morantel, thiamphenicol, pyrimethamine, 
furazolidone, oxalinic acid, difurazon, nalidixic acid, and piromidic acid) in porcine 
muscle. After extraction and clean up, a C|g column with gradient elution was utilised for 
the separation and CID was used to induce fragmentation of analyte molecules and 
enhance the specificity of the method (Fuh et al., 2000).
As previously mentioned (see Section 1.13.2.) CBX, monoxy-CBX and desoxy-CBX, 
disappear from tissue after < 72 hours of the withdrawal of medication (Macintosh et al., 
1985), through either metabolism or excretion via urine or bile. Methods for the direct 
detection of CBX or related residues would therefore be ineffective in tissue at slaughter, 
if medication had ceased before this time. This effectively precludes the use of all 
published detection methods for CBX to pharmacokinetic, pharmaceutical and 
feedingstuff analysis.
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After the withdrawal of CBX as a zootechnical feed additive by the EU on 31st August 
1998, all suitable feedingstuff methods need to be capable of analysis at trace 
concentrations. EU criteria state that methods based only on chromatographic analysis 
without the use of molecular spectrometric detection are not suitable on their own as 
confirmatory methods. This excludes chromatographic separation with UV/Vis detection 
as a confirmatory method (though HPLC methods may be used for screening feed if they 
have a sufficiently low detection capability). Therefore in the EU, only the methods based 
on molecular spectrometry (MS and fluorescence detection) can be used to confirm the 
presence of CBX in feeds. No currently published methods for the analysis of CBX in 
animal feedingstuffs meet EU criteria for use as a confirmatory method. A current 
requirement within the EU is for a confirmatory method for CBX in medicated 
feedingstuffs.
1.15.2. Detection of quinoxaline carboxylic acid in tissue
One of the earliest methods was published by Lynch and Bartolucci (1982) and involves 
extraction followed by derivatization and gas-liquid chromatography-MS using SIM. 
QCA was first isolated from hydrolysates of porcine liver samples by solvent extraction 
and ion exclusion chromatography. The relative intensities of three ions were monitored: 
the base peak at m/z 130, a second mass at m/z 158, and the molecular ion (M-H+) at m/z 
188. This was adopted as the reference method in the EU for the determination of QCA in 
tissue (Commission of the European Communities, 1992). Using a similar extraction 
method Lauridsen et al. (1988) applied the increased detection capability of gas 
chromatography linked to electron capture mass spectrometry to quantify QCA at lower 
concentrations (~ 10 pg kg '). Lynch et al. (1988) again using a similar extraction method
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further improved on this technique and reported a method using analysis via ion trap 
detector (TID) connected to a capillary GC using Cl conditions. A tetradeutrated internal 
standard was included in the method to compensate for losses during the extraction 
procedure. This allowed QCA detection down to 3 pg kg'1. Van Ginkel et al. (1990) 
described a tissue method based on the enzymatic digestion of the tissue, derivatization of 
the extract and clean up using HPLC followed by GS-MS analysis. Subsequent 
confirmation of QCA was at m/z 102, 130 and 158 with calculation of the in-sample 
concentration by comparison of the QCA ion at m/z 130 to tetradeutrated QCA at m/z 134. 
This method now allowed detection of QCA as low as 1-2 pg kg'1.
Initially the GC-MS methods were used in preference to HPLC as the separation of QCA 
was recognised as difficult and consequently hard to apply. Rose et al. (1995) using the 
extraction method developed by Van Ginkel et al. (1990) and a cation exchange 
procedure, produced an HPLC method linked to UV/Vis detection. This offered 
significant advantages over GC-MS methods, as costly equipment was not necessary to 
apply the technique to surveillance and monitoring. However, an MS method would still 
be required for confirmation of positive samples.
The EU has published criteria that must be applied to the confirmation of residues in 
animals and animal products of food origin. None of the previously published methods for 
detection or confirmation of QCA in tissues meets such stringent requirements. 
Furthermore they are slow, cumbersome and do not have the advantage of being able to 
handle large numbers of samples. A current requirement within EU is for a rapid, sensitive 
QCA confirmatory method that will meet all the criteria for method validation.
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1.15.3. Detection of olaquindox in feedingstuffs and tissue
In the late 1970s the analysis of OQX was described by Bories (1979), who recognised 
that HPLC could be applied to the analysis of OQX in feed to give a fast, accurate and 
reproducible method of analysis. OQX was first extracted from the feed matrix by 
homogenisation with potassium carbonate in acetonitrile. OQX’s polar character was 
exploited using an iso-octane partition that removed many common non-polar interfering 
substances. Reverse phase chromatography was carried out using a Sperisorb (250 x 
21mm) 5pm Cjg LC column and a simple methanol-water mobile phase (5 : 95 v/v) at a 
rate of 1.2 ml min'1. Before this time OQX feed analysis was mainly carried out using 
time-consuming TLC that involved the extensive clean up of crude feed extract to 
eliminate interferents (Fink and Kreisner, 1982).
In the 1980s as HPLC replaced TLC as the separation method of choice. Thente and 
Anderson (1982) described a feed method that did not involve prior extract purification, 
however, though rapid, due to the removal of the liquid - liquid partition step, subsequent 
clogging of the HPLC column limited the usefulness of the method. The Analytical 
Methods Committee (1985) of the Analyst produced a similar simple single step 
extraction procedure for the HPLC of OQX in feeds. In the same year Botsoglou et al. 
(1985) reported a simple single step method for OQX analysis in feed using aqueous 
extraction, filtration, and then analysis by 2nd derivative UV spectrophotometry. However, 
by this method of analysis estimations of the drug level in the feed sample were only 
possible.
The above-mentioned methods only allow quantification of the drug at feed medication 
levels and did not permit analysis down to trace levels. The published methods were also
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only concerned with the analysis of OQX in meal. Nagata and Saeki (1987) recognised 
this problem and reported a method for the extraction, and clean up, in swine tissue. OQX 
was extracted with acetonitrile and dried down, followed by clean up using alumina 
column chromatography. HPLC analysis with ultraviolet detection at 350 nm was on 
Nucleosil Clg LC column using a simple acetonitrile/water (5:95 v/v) mobile phase. The 
detection limit for this method was 0.02 ppm in tissue. This was followed by Speirenburg 
et al. (1988a) using HPLC for the determination of OQX in both medicated feeds and the 
contents of the porcine gastrointestinal tract. Samples were extracted with water and 
cleaned on disposable solid phase extraction columns under isocratic conditions. This 
method allowed investigation of the concentration profiles of OQX in the gastrointestinal 
tract of pigs fed medicated feed, to evaluate the potency of OQX against Treponema 
hyodysenleriae. The presence (in the gastrointestinal tract) of some N-O reduced 
metabolites of OQX was also assessed.
Recently, mass spectrometry linked to HPLC has been applied to the analysis of OQX in 
swine feed and meat samples by Fuh et al. (2000). This method allowed the determination 
of 13 different anti-bacterial compounds in the same sample. CID was used to induce 
fragmentation of analyte molecules and enhance the specificity of the method and SIM 
was employed for quantitative determination.
OQX is rapidly metabolised in vivo to MQCA, limiting the usefulness of methods for the 
detection of OQX to pharmaceutical and medicated feedingstuff analysis. After the 
withdrawal of OQX as a zootechnical feed additive by the EU on 31st August, 1998, all 
suitable feedingstuff methods need to be capable of analysis at trace concentrations. EU 
criteria for confirmatory techniques require that specific structural information be
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provided by the method of analysis. This precludes all currently published HPLC methods 
with UV/Vis detection to be used as a means of screening feed for the presence of OQX, if 
they have a sufficiently low detection capability. Only methods based on molecular 
spectrometry (mass spectrometry and fluorescence detection) can be used for confirmation 
of OQX in feeds. No currently published methods for the analyses of OQX in animal 
feedingstuffs meet all current EU criteria for use as a confirmatory method. A current 
requirement within the EU is for a confirmatory method of OQX in medicated 
feedingstuffs.
1.15.4. Detection of methyl quinoxaline carboxylic acid in tissue
Problems with CBX residues and their detection have already been recognised and to an 
extent addressed, as CBX was in wide-spread use through out the world as a zootechnical 
feed additive in the 1980s and 90s. However, the same is not true of OQX and MQCA. In 
addition to this, MQCA was only established as the marker residue for OQX in 1995 and 
many NRLs have yet to develop and implement confirmatory methods for use in their 
National Surveillance Schemes. A current requirement within EU is for a rapid, sensitive 
MQCA confirmatory method that will meet all the criteria for method validation.
1.16. Objectives
Member States must implement monitoring schemes for drug residues in animals and 
animal products in order to comply with EU regulations. Such legislation also contains 
lists of compounds to be tested in addition to rules for the use and performance of 
analytical screening and confirmation methods. If a method does not currently exist or 
does not meet current regulations, a previously applied analytical method must be 
improved or a new method developed. Ideally, each Member State NRL would be able to
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analyse all the licensed veterinary products to ensure compliance with all EU regulations 
and enforce any ban on the use of a compound. However, this is not possible in practice 
and is still a distant prospect for some laboratories. National monitoring programmes often 
reveal specific problems involving a drug or related residues within their agricultural 
sector. The confirmatory analytical methods reported in literature for the analysis of such 
compounds are not always suitable through the publication of new regulations, changes in 
analytical technology or marker residue. In such cases, steps should be taken by the 
individual Member State to resolve such problems. The work presented in this thesis 
addresses several such problems found in NI and the EU.
The objectives of the work were as follows:
1 (A) To develop a rapid confirmatory method at contamination levels for the 
zootechnical feed additives, CBX and OQX in porcine rations as EU Commission 
Regulation No 2788/98 prohibits the use of either compound in livestock farming 
following the withdrawal off their product licences.
(B) To validate the developed method as defined by the current regulations for 
analytical method validation laid out in EU Commission Decision 2002/657/EC, to 
allow application of the method to the statutory testing of samples in NI taken under the 
UK National Surveillance Scheme complying with EU Council Directive 96/23/EC.
2 (A) To develop a fast and robust confirmatory method for the CBX marker residue in 
porcine tissue, QCA, due to the prohibition of the use of CBX in livestock farming.
(B) To validate the developed method as defined by regulations for EU analytical 
method validation as laid out in EU Commission Decision 2002/657/EC.
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(C) To compare the developed method to the current in-house GC-MS method and to 
allow application to the statutory testing of samples in NI taken under the UK National 
Surveillance Scheme and Meat Inspection Scheme complying with EU Council 
Directive 96/23/EC.
3 (A) To investigate if the CBX metabolite, QCA, can be transferred from a group of 
medicated animals to a group of unmedicated animals through the use of the same 
housing, leading to a ‘violative’ laboratory result, as previously demonstrated with the 
antimicrobial furazolidone by this laboratory (McCraacken et ai, 2000).
(B) If such transfer occurs, to investigate possible ways of differentiating between 
residues generated due to contamination of the housing and deliberate medication of 
the animals.
4 (A) To develop a fast and robust confirmatory method for the OQX marker residue in 
porcine tissue, MQCA, due to the prohibition of the use of OQX in livestock farming. 
(B) To validate the developed method as defined by regulations for EU analytical 
method validation as laid out in EU Commission Decision 2002/657/EC, so the 
method may be applied to the statutory testing of samples in NI taken under the UK 
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The objectives of the work presented in this chapter were:
(A) To develop a rapid confirmatory method at contamination levels for the zootechnical 
feed additives, CBX and OQX in porcine rations as EU Commission Regulation No 
2788/98 prohibits the use of either compound in livestock farming following the 
withdrawal off their product licences.
(B) To validate the developed method as defined by the current regulations for analytical 
method validation laid out in EU Commission Decision 2002/657/EC, to allow application 
of the method to the statutory testing of samples in N1 taken under the UK National 
Surveillance Scheme complying with EU Council Directive 96/23/EC.
Both CBX and OQX were used throughout the 1980s and 90s in the livestock industry and 
veterinary medicine as zootechnical feed additives and anti-microbial agents throughout 
the world. CBX’s use as a growth promoter, was in addition to its prophylactic properties 
in the prevention of swine dysentery and bacterial enteritis in young swine (see Chapter 
1.13.). OQX is a quinoxaline 1,4-dioxide structurally related to CBX, but was mainly sold 
only as a growth stimulant (see Chapter 1.14.). The use of both as feed additives was at 
medicated concentrations infeed from 50 - 100 mg kg'1. In 1998, both drugs were 
prohibited from use in livestock production within the EU due to carcinogenic and 
mutagenic concerns (European Commission, 1998). Any sample taken within the EU 
generating a result other than zero is therefore considered non-compliant. CBX and OQX 
are still licensed for use as feed additives in other non-EU countries and are available as 
premixed zootechnical feed products e.g. Mecadox 10 (Pzifer) and Bayo-N-OX (Bayer). 
Thus, the potential for illegal use of both drugs still exists inside the EU. Publications have
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shown that drugs at low levels can be carried over from one batch of medicated feed into 
several subsequent batches of unmedicated feed (Kennedy et al, 1998a; Lynas et ai, 
1998), causing unwanted and illegal residue levels in tissue (Blanchflower et al., 1993b). 
It is therefore important that the method is capable of determination of both drugs at low 
levels in feed, to aid both the feed industry and national authorities to spot sources of 
contamination and eliminate them.
Previously published methods for the detection of CBX or OQX in feed have been based 
on HPLC coupled to UV or fluorescence as a means of detection. New EU regulations for 
systemic method validation were published in 2002 superseding all previous criteria (see 
Section 1.11.). None of the currently published methods met these new criteria for the 
confirmation of either drug. This chapter describes a method that allows the confirmation 
of both banned compounds within the same sample using LC linked via electrospray to 
MS-MS and meets new EU criteria. The accuracy and precision were assessed at low 
concentrations to mimic contamination levels in feed (0.5-5.0 mg kg'1). The simple 
extraction followed by MS analysis offers considerable advantages in terms of the number 
of samples that can be processed by an operator in one batch.
2.2. Experimental
2.2.1. Materials
All solvents were of HPLC grade and all other chemicals were of analytical reagent grade. 
Distilled or de-ionised water was used throughout the study. Both CBX and OQX were 
obtained from ICN Biochemicals Ltd (Oxfordshire, UK). The mobile phase was 
acetonitrile-water-formic acid (17.5 : 82.4 : 0.1 v/v), which was filtered and degassed
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under vacuum through a 0.45 jam filter and stable for 1 month when stored at room 
temperature.
2.2.2. Standards
All standards were prepared in amber glassware. Stock standard solutions (1.0 mg ml'1) of 
both drugs were prepared in N,N-dimethylformamide (DMF) and were stable for at least 6 
months. A mixed intermediate standard solution (10 pg ml1) was prepared by pipetting a 
volume (1 ml) of each stock standard solution in to a 100 ml volumetric flask, which was 
then made up to the mark with acetonitrile. Mixed working standard (1.0 pg ml'1) was 
prepared by dilution of the mixed intermediate standard with acetonitrile. Mixed standards 
were stable for at least 3 months. Standard solutions were all stored at 4°C in amber vials.
2.2.3. Spiking solution for validation
Spiking solution 1 (50 pg ml"1) was prepared by pipetting a volume (5 ml) of each stock 
standard solutions (1.0 mg ml'1) into a 100 ml volumetric flask, which was then made up 
to mark with acetonitrile. Spiking solutions 2 (25 pg ml'1) and 3 (5 pg ml'1) were prepared 
by dilution of spiking solution 1 (50 pg ml"1) with acetonitrile. Spiking solutions were all 
stored at 4 °C in amber vials and were stable for at least 3 months.
2.2.4. Equipment
Electrospray LC-MS-MS System
The HPLC system consisting of a Hewlett-Packard (Stockport, Cheshire, UK) series 1100 
LC pump, autosampler and solvent degasser were coupled via an electrospray interface to
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a Quattro LC (Micromass, Wythenshawe, UK). The LC column used was a Luna 5|a Cig 
250 x 4.6 mm (Phenomenex, Macclesfield, Cheshire, UK) with a 5|a Cig column guard 
(Phenomenex, Macclesfield, Cheshire, UK) attached. The mobile phase was pumped at a 
rate of 1 ml min'1, with the column eluant being split so that approximately 200 pi min"1 
entered the mass spectrometer. The mass spectrometer was run in electrospray positive 
mode, with the MS source maintained at 150 °C. Nitrogen was used as the drying and 
nebulising gas at a flow rate of -600 and 80 1 h'1, respectively. The injection volume was 
50 pi and the total run time per sample was 15 min. Spectra for CBX and OQX were 
obtained over the range m/z 50-300 with the instrument configured for MS only.
2.2.5. Sample Extraction
Samples of meal were pulverised, if necessary, in a knifetec 1095 sample mill (Tecator, 
Hoganas, Sweden). Aliquots of test or control meal (10.0 ± 0.1 g) for analysis were 
weighed into 125 ml polythene bottles. Four recovery samples fortified at 1.0 mg kg'1 
were prepared by the addition of mixed intermediate standard solution (1ml) to known 
negative meal. In addition, two known negative samples, two matrix standard samples and 
two check samples were analysed with every batch. The check samples are samples 
fortified with CBX and OQX at a concentration unknown to the analyst. Fortified samples 
for validation purposes were also prepared at this stage by addition of spiking solutions 1, 
2 or 3 (50, 25 or 5 pg ml1, 1 ml) onto known negative meal giving CBX and OQX 
recovery levels at 5, 2.5 and 0.5 mg kg'1, respectively. The samples were allowed to stand 
for 10 min before proceeding. Acetonitrile-chloroform solution (50 : 50 v/v, 50 ml) was 
added and each sample placed on a mechanical shaker for 1 hour. The solutions were 
centrifuged (2000g, 4 °C, 10 min.) and 1 ml of the solvent extract transferred into a clean
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3 ml glass tube. Matrix working standards were prepared at this stage by pipetting mixed 
working standard solution (1.0 pg ml"1, 1 ml) plus matrix standard extract (1 ml) into a 
clean 3 ml glass tube. The solvent was removed from samples and matrix standards by 
drying under a stream of nitrogen at 65 ± 5 °C. The remaining residue in each tube was re­
dissolved in mobile phase (1 ml) by sonication for 10 min. Aliquots of each solution (200 
pi) were transferred into microvials for analysis.
2.2.6. LC-MS-MS analysis
For each sample or matrix standard ran, the instrument was initially configured for 
multiple reaction monitoring (MRM) of OQX from 0 to 6 minutes. Quadrupole 1 was set 
to transmit the molecular ion ([M+H]+) of OQX (m/z 264) and quadrupole 2 set to transmit 
the MS-MS product ions at m/z 212 and 143. The collision energies were 20 and 35 eV, 
respectively. From 6 to 15 min the instrument settings were switched to enable for the 
MRM of CBX. Quadrupole 1 was set to transmit the molecular ion ([M+H]+) of CBX (m/z 
263) and quadrupole 2 set to transmit the MS-MS product ions at m/z 231 and 90. The 
collision energies were 15 and 30 eV, respectively. The collision entrance and exit 
energies were set to 0 and 2 eV, respectively for all MRM. The collision gas, argon, was 
bled into the cell at a pressure of 2.3 x 10"3 mbar. The dwell time for all ions was 0.5 sec. 
Results for OQX were calculated by comparing the response of m/z 264 —> 143 (OQX 
base peak) in the samples with the mean of the m/z 264 —» 143 response for the matrix 
working standards (1.0 pg ml'1) in the run which were equivalent to 5.0 mg kg"1. Results 
for CBX were calculated in a similar way, by comparing the response of m/z 263 -» 231 
(CBX base peak) in the samples with the mean of the m/z 263 —> 231 response for the
-78-
matrix working standards (1.0 (xg ml'1) in the run which were again equivalent to 5.0 mg 
kg'-
2.3. Results and Discussion
2.3.1. Tandem MS analysis of carbadox and olaquindox
Both CBX and OQX gave a strong response in electrospray positive mode, with 
prominent peaks for the [M+H]+ ions at m/z 263 and 264, respectively; MS-MS of the m/z 
263 [M+H]+ molecular ion of CBX produced two prominent product ions at m/z 231 (base 
peak) and 90 (Figure 2.1. A). The transition m/z 263 —>■ 231 probably results from the loss 
of the two co-ordinate covalent oxygen atoms from the [M+H]+ molecular ion. The m/z 
263 —> 90 transition may result from the loss of the quinoxaline ring (Figure 2.1 .A). The 
MS-MS of the m/z 264 [M+H]+ molecular ion of OQX (Figure 2.1. B) also produces two 
prominent product ions at m/z 212 and 143 (base peak). The m/z 264 ->212 product 
probably represents the loss of one of the co-ordinate covalent oxygen atoms as well as the 
loss of HaO and a hydroxyl. The m/z 264 -> 143 product ion is thought to be produced as 
a result of the subsequent loss of the side chain (Figure 2.1. B).
According to the EU’s technical criteria for the identification of veterinary drugs a 
minimum of 4 identification points (IP) are required for the confirmation and 
unambiguous identification of unauthorised compounds. According to the revised criteria 
1.5 IP is given for each MS-MS product ion measured (and 1 IP for the precursor ion). 
The described method, which measures 2 product ions (+1 precursor ion) for each 
compound scores 4.0 IPs for CBX and OQX. This fulfils the minimum identification 
criteria needed.
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Fig. 2.1. MS-MS spectra of CBX (A) and OQX (B), including the structure of the proposed diagnostic
ions.
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However, the ion ratios for each unknown sample must also correspond (within predefined 
limits) to those measured in the standards within the run for unambiguous identification. 
In this method the ratio of m/z 263 : 90 and m/z 263 : 231 were measured for CBX with 
m/z 264 : 212 and m/z 264 : 143 measured for OQX. All of these results had to meet the 
pre-set tolerances stated in criteria before they could be considered acceptable (see 
Chapter 1.11.1). All the samples used in the validation study were subject to, and met, the 
above stated identification criteria.
Calculation of results is by comparison to standards made with sample matrix, so that any 
enhancement or suppression of the signal may be compensated for within the run. Such 
effects can otherwise make the computation of recoveries and results difficult due to 
variation in the required ion ratios for identification, as well as the absolute peak areas 
being affected.
2.3.2. Method performance characteristics
This extraction method was developed by simplifying and modifying several published 
techniques for the extraction of CBX or OQX from feed and combining them to allow the 
dual extraction of both drugs (Botsoglou et ah, 1985; Goras et ah, 1974; Lowie et al., 
1983; Nagata and Saeki, 1987). Due to the simplicity of the method and the single 
extraction step, up to 20 sample could be prepared (including check samples and 
standards) for analysis within half a working day.
Figure 2.2. shows MRM chromatograms for CBX and OQX standards (equivalent to 5.0 
mg kg '), a negative meal and a meal fortified with CBX and OQX at 0.5 mg kg’1. Both 
compounds show good chromatography. The negative meal is free of interfering peaks at
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the retention times of the analytes and only shows baseline signal over the time window, 
proving they are truly negative. Standards were prepared by fortifying extracted negative 
sample matrix, as described above. This approach was used to ensure that any 
enhancement or suppression of the signal caused by the presence of matrix is compensated 
for in the standards included in each batch.
Validation of the method was performed by the analysis of different negative porcine feed 
samples which had been fortified at 3 different levels (n=6 at each level) on each of three 
days by one operator. Since Commission Decision 2002/657/EC applies to testing for 
residues in animals and animal products, MRPLs have not been (and will not be) 
established for CBX and OQX in feed. Consequently, it was not necessary to calculate 
some of performance characteristics, such as CCa and CCP, listed in that decision (see 
Chapter 1.11.5 and 1.11.6). Porcine feeds were used for the validation studies, as this 
laboratory is required to test only porcine feed for the presence of these compounds. The 
concentrations of CBX and OQX chosen to assess the accuracy and precision of the 
method were 0.5, 2.5, and 5.0 mg kg"1. The results for CBX and OQX are presented in 
Table 2.1. and Table 2.2., respectively. The mean recovery of the assay for CBX was 86.4 
% and for OQX was 78.3 %. The Limit of Determination for this method is 0.5 mg kg"1 as 
this is the lowest concentration at which the described method has been validated with a 
specified degree of accuracy and precision. The Detection Limit (based on a signal: noise 
ratio of 3 : 1) achievable by this method is approximately one order of magnitude lower 
for each compound (i.e. approximately 50 pg kg"1). The Detection Limit of this 
electrospray LC-MS method is comparable to that achieved by Fuh et al, (2000), which 
claimed a Detection Limit of 0.2 mg kg"1 for OQX and 0.05 mg kg"1 for CBX.
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Fig. 2,2. MRM chromatograms for: A) matrix standard (equivalent 5 mg kg'1)* E) a known negative 
meal and C) a negative meal spiked with CBX and OQX at 0.5 mg kg'1 for each drug.
-83 -
Table 2.1. Inter- and intra-assay reproducibility and recovery for known negative meal spiked with 
CBX at 0.50, 2.50 and 5.00 mg kg'1.
0.50 mg kg"1 2.50 mg kg"1 5.00 mg kg'1
Day 1
Mean 0.50 2.27 3.97
s 0.04 0.08 0.32
RSD 7.70 3.70 8.20
% Recovery 99 91 79
n 6 6 6
Day 2
Mean 0.41 1.94 3.51
s 0.02 0.06 0.13
RSD 4.20 3.00 3.60
% Recovery 82 78 70
n 5 6 6
Day 3
Mean 0.40 1.88 3.53
s 0.02 0.06 0.09
RSD 4.50 3.30 2.60
% Recovery 80 75 71
n 6 6 6
Overall
Mean 0.44 2.03 3.67
s 0.05 0.19 0.29
RSD 11.74 9.22 7.92
% Recovery 88 81 73
n 17 18 18
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Table 2.2. Inter- and intra-assay reproducibility and recovery for known negative meal spiked with 
OQX at 0.50, 2.50 and 5.00 mg kg"1.
0.50 mg kg'1 2.50 mg kg"1 5.00 mg kg'1
Day 1
Mean 0.38 2.11 4.06
s 0.04 0.09 0.41
RSD 11.00 4.30 10.00
% Recovery 76 84 81
n 6 6 6
Day 2
Mean 0.38 1.92 3.65
s 0.04 0.17 0.38
RSD 11.3 8.90 10.30
% Recovery 75 77 73
n 5 6 6
Day 3
Mean 0.40 1.98 3.85
s 0.02 0.14 0.26
RSD 4.60 7.20 6.70
% Recovery 80 79 77
n 6 6 6
Overall
Mean 0.39 2.00 3.86
s 0.03 0.15 0.37
RSD 8.78 7.71 9.67
% Recovery 77 80 77
n 17 18 18
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Their method was developed to measure these compounds in pork meat. However, the 
appropriate marker residues for OQX and CBX in meat are not the parent drugs, but are 
methyl quinoxaline-2-carboxylic acid and quinoxaline-2- carboxylic acid, respectively. 
Furthermore, the chromatograms presented for the determination of OQX showed the 
presence of a substantial interfering peak. Finally, the method Fuh et al. (2000) did not 
address the issue of analyte identification by measurement of characteristic fragment ions. 
Thus, it is not suitable for use as a confirmatory method under current EU legislation.
2.4. Conclusion
Previous publications have shown that low levels of drug can be carried over from one 
batch of medicated feed into several ensuing batches of unmedicated (blank) feed (Lynas 
et al., 1998). This contamination of feed with unlisted drugs has been shown to cause 
‘violative’ residue concentrations in tissue, leading to the possible condemnation of all 
related carcasses and prosecution of an ‘innocent’ producer.
The method presented is both rapid and simple and will allow measurement of 
contamination levels of CBX and OQX in both commercially produced meal and 
experimental formulations. Approximately 20 samples, excluding controls and negatives, 
can be extracted and prepared for analysis in half a working day. The method has been 
validated according to EU Commission Decision 2002/657/EC over the concentration 
range 0.5 - 5.0 mg kg'1 for both compounds.
The Limit of Determination for this method is 0.5 mg kg'1 as this is the lowest 
concentration at which the described method has been validated with a specified degree of 
accuracy and precision. The Detection Limit (based on a signal: noise ratio of 3 : 1)
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achievable by this method is approximately one order of magnitude lower for each 
compound (i.e. approximately 50 pg kg"1).
The method has been applied to the analysis of samples taken in NI under the UK National 
Surveillance Scheme. The objectives set for this chapter have therefore been fulfilled.
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2.5. Publications
The method described in this chapter was submitted to the Food Additives and 
Contaminants in 2003 under the title:
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., Development and validation of a 
method for confirmation of carbadox and olaquindox in porcine feedingstuffs using LC - 
electrospray MS-MS.
The method described in this chapter was presented in poster format at the Fourth 
International Symposium on Hormone and Veterinary Drug Analysis, Antwerp, Belgium 
in 2002 under the same title.
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Chapter 3
Determination of the carbadox metabolite, quinoxaline-2- 
carboxylic acid, in porcine liver using liquid chromatography 
electrospray tandem mass spectrometry
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3.1. Introduction
The objectives of the work presented in this chapter were:
(A) To develop a fast and robust confirmatory method for the CBX marker residue in 
porcine tissue, QCA, due to the prohibition of the use of CBX in livestock farming.
(B) To validate the developed method as defined by regulations for EU analytical method 
validation as laid out in EU Commission Decision 2002/657/EC.
(C) To compare the developed method to the current in-house GC-MS method and to 
allow application to the statutory testing of samples in NI taken under the UK National 
Surveillance Scheme and Meat Inspection Scheme complying with EU Council Directive 
96/23/EC.
National Surveillance Schemes for veterinary drug residues are required to monitor for the 
use of CBX in animals for human consumption. QCA is the most persistent metabolite of 
CBX and has been designated the marker residue for CBX use in animals (Ferrando et al., 
1975). Before the withdrawal of the product licence for CBX, the MRL for QCA in liver 
was set at 30 pg kg'1. Now the presence of any confirmed concentrations of QCA in a 
sample is considered a non-compliant result. No MRPL has yet been set for QCA. The EU 
has revised the criteria applied to the screening and confirmation of veterinary drug 
residues in animals of food origin (see Chapter 1.11.). None of the previously published 
methods meets these new technical criteria. Furthermore, the existing methods are slow, 
cumbersome and are not applicable to large numbers of samples. The described assay for 
the confirmation of the CBX metabolite in porcine liver uses liquid chromatography 
linked via an electrospray interface to tandem mass spectrometry and meets all the EU’s 
new technical criteria. The method also offers considerable advantages in terms of the
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number of samples that can be processed by an operator in one batch. The accuracy and 
precision of the method were accessed over a wide concentration range (3-300 pg kg'1) to 
reflect field samples collected in NI. Correlation between the described method and the in- 
house routine method, based on high resolution gas chromatography MS, was assessed 




All solvents were of HPLC grade and all other chemicals were of analytical grade. 
Distilled or de-ionised water was used throughout the study. Deuterium labelled 
Quinoxaline-2-Carboxylic Acid (cfi-QCA) from RIVM (European Union Community 
Reference Laboratory, Bilthoven, The Netherlands) was employed as an internal standard. 
QCA was obtained from Sigma-Aldritch Co. Ltd. (Gillingham, Dorset, UK). Stock 
standard solutions of QCA (1.0 mg ml'1) and cfi-QCA (10 pg ml'1) were prepared in 
methanol. Working standards for both (1.0 pg ml'1) were prepared by serial dilutions of 
the stock standards in methanol. Stock standards were stable for 1 year and working 
standards were stable for 3 months, when stored in amber vials at 4 °C. The back 
extraction solution was 0.1 M sodium phosphate buffer, pH 8.0. The mobile phase, 
methanol-water-acetic acid (40 : 59.6 : 0.4 v/v), was filtered and degassed before use.
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3.2.2. Equipment
Solid Phase Extraction System
Solid phase extraction (SPE) was carried out on an ASPEC XL4 coupled to a 404-syringe 
pump (Gilson Ltd, Middleton, Wisconsin, USA) using 1ST non-endcapped 
benzenesulfonic acid (SCX), 3 ml, 1.0 g sorbent material, disposable extraction columns 
(1ST Ltd, Mid. Glamorgan, UK). These were wetted with methanol (5 ml, 2.5 ml min'1; 
0.3 ml air push, 3 ml min"1) and conditioned with hydrochloric acid (0.1 mol L1, 5 ml, 2.5 
ml min'1; 0.3 ml air push, 3 ml min '). The sample was applied onto the cartridge (2ml, 1 
ml min'1; 3 ml air push, 1 ml min'1) and washed with a further aliquot of hydrochloric acid 
(0.1 mol l'1, 5 ml, 2.5 ml min'1; 0.3 ml air push, 3 ml min '). The cartridge was eluted with 
0.1 mol l'1 sodium hydroxide-methanol solution (70 : 30 v/v) into 10 ml glass tubes (3 ml, 
1 ml min'1; 3 ml air push, 1 ml min1).
Electrospray LC-MS-MS System
All tandem MS analyses were performed using a Quattro LC mass spectrometer 
(Micromass, Wythenshawe, UK) in positive mode. A Hewlett Packard HPLC system 
(Stockport, Cheshire, UK) comprising a 1100 series binary pump, autosampler and solvent 
degasser was coupled via an electrospray interface to the Quattro LC. The HPLC column 
used was a Columbus Sp Cig 150 x 4.60 mm (Phenomenex, Macclefield, Cheshire, UK). 
The mobile phase was pumped at a rate of 1.0 ml min'1 with the column effluent split so 
that approximately 200 pi min'1 entered the mass spectrometer. The total run time was 15 
min. The MS source was maintained at 150 °C with nitrogen used as the drying and 
nebulising gas at a flow rate of 500 and 80 1 h'1, respectively. The collision gas, argon was 
bled into the cell at a pressure of 2.3 x 10"3 mbar.
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High Resolution GC-MS System
All high-resolution GC-MS analyses were performed using a three-sector double focusing 
mass spectrometer (VG autospec, VG Analytical, Manchester, UK). A HP5890 gas 
chromatograph fitted with a HP7673 autosampler (Stockport, Cheshire, UK) was coupled 
via a transfer line to the mass spectrometer. The GC column was a 25m x 0.25mm x 
0.25pm Rtx-1 (Restek, Bellefonte, Arizona, USA) capillary column. The injection port 
temperature was set at 280 °C. The pre-run oven temperature was 100 °C, which was 
ramped to 200 °C at 10 °C min'1, and then to 280 °C at 50 °C min'1. The run time per 
sample was 12 min. The instrument was operated in El positive mode with an electron 
energy of 70 eV and a trap current of 300 pA. The temperature of the source and transfer 
line were held at 200 °C and 290 °C, respectively. The magnet was set at a lock mass of 
m/z 198.988 and the instrument calibrated using perfluoronbutylamine.
3.2.3. Tissue Extraction
Aliquots of homogenised test or control liver (5.00 ± 0.05 g) were weighed into 35 ml 
glass tubes. Two known negative samples were analysed in every batch. In addition, four 
recovery samples, fortified at 30 pg kg'1 were prepared by adding QCA working standard 
solution (150 pi) to known negative tissue. A further two check samples were analysed 
with every batch. These were known negative samples that had been fortified with QCA at 
a concentration unknown to the analyst. Fortified samples for validation purposes were 
also prepared at this stage by addition of the relevant amount of standard solution. Internal 
standard, cfi-QCA (150 pi of the 1.0 pg ml'1 working standard) was added to each sample. 
Sodium hydroxide solution (3 M, 10 ml) was added to each sample and all were placed in 
a water bath set at 100 °C for 30 min. The samples were removed and allowed to cool to
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room temperature. Concentrated hydrochloric acid (4 ml) was added to each tube and the 
contents mixed for 30 sec. Ethyl acetate (6 ml) was added and the tubes invert for 1 min 
and centrifuged (2000g, 4 °C, 10 min.) The upper layer was transferred into a 
polyethylene tube (50 ml) and the extraction repeated. The two extracts were then 
combined. Back extraction solution (8 ml) was added and the tubes inverted for 1 min and 
centrifuged (2000g, 4 °C, 10 min.). The upper organic layer was aspirated to waste and an 
aliquot (4 ml) of the aqueous phase transferred to a 10 ml glass tube containing 
concentrated hydrochloric acid (1 ml). Solid phase extract was then carried out as 
described in Section 3.2.2. To each SPE cartridge eluate, concentrated hydrochloric acid 
(300 pi) was added. Ethyl acetate (2 ml) was added and the tubes vortexed for 15 s and 
then centrifuged (2000g, 4 °C, 10 min.). The upper organic layer was transferred into glass 
centrifuge tubes. The extraction was repeated a further two times and the extracts were 
combined. The ethyl acetate extracts were taken to dryness under a stream of nitrogen at 
60 °C. Methanol-water solution (10 : 90 v/v, 100 pi) was added, and the tubes were 
vortexed for 15 sec. The solutions were then transferred to microvials for analysis.
3.2.4. Tandem MS analysis
Spectra for QCA and d4-QCA were obtained over the range m/z 50-200 with the 
instrument configured in MS mode only. For multiple reaction monitoring (MRM), 
quadrupole 1 was set to transmit the molecular ion ([M + H]+) of QCA {m/z 175) and d4- 
QCA {m/z 179). Quadrupole 2 was set to transmit the QCA product ions at m/z 129, 102 
and 75 along with the d4-QCA product ion at m/z 106. The collision cell entrance and exit 
energies were set at 0 and 2 eV, respectively. The collision energy was optimised at 15, 
30 and 45 eV for the QCA product ions at m/z 129, 102 and 75, respectively. The collision 
energy was optimised at 30 eV for the dt-QCA product ion at m/z 106. The dwell time for
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each ion was 0.3 sec. Pumping mobile phase for 15-20 min. before analysis equilibrated 
the system. The injection volume was 30 pi. Working standard standards (QCA, dj-QCA, 
30 pg kg'1) were run on the LC-MS-MS system above until reproducible peak areas were 
obtained. Aliquots of sample extract were then injected, with a standard after every 4 
samples. Concentrations for QCA were calculated by comparing the ratio of the m/z 175 
-> m/z 129 response (QCA) with the m/z 179 —> 106 response (cft-QCA) in the samples 
with those in the standards (30 pg kg ') included in the run.
3.2.5. GC-MS Analysis
For QCA analysis, the instrument was run in single ion monitoring (SIM) mode. The ions 
at m/z 102.034, 130.053, 158.048 and 188.058 were monitored for QCA and m/z 192.083 
for cft-QCA. The resolution was set at 5,000 and multiplier voltage at 400 V. The injection 
volume was 1.5 pi in splitless injection mode. Working standard standards (QCA, d4- 
QCA, 30 pg kg'1) were run on the GC-MS system above until reproducible peak areas 
were obtained. Aliquots of sample extract were then injected with a standard after every 4 
samples. Concentrations were calculated by comparing the peak ratio of the base peak 
(m/z 188.058) with the equivalent ion (m/z 192.083) for the internal standard in the sample 
with the mean ratio (m/z 188.058 : 192.083) of the standards (30 pg kg'1) in the run.
3.3. Results and Discussion
3.3.1. Tandem MS analysis of quinoxaline carboxylic acid
MS-MS of the m/z 175 [M + H]+ molecular ion of QCA (see Fig. 3.1) produces three 
prominent products at m/z 129, 102 and 75. The abundance of each product ion was 
optimised at collision energies of 15, 30 and 45 eV, respectively. The product ion formed
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at m/z 129 results from the successive loss of water and carbon monoxide. This is
supported by the observation of a small peak at m/z 157 (loss of H2O) in the trace at 15 
eV. The other product ions {m/z 102 and 75) were formed by two successive losses of 
HCN from the molecule. New EU technical criteria require a minimum of 4 IPs to 
unambiguously confirm unauthorised substances in food of animal origin. The criteria 
score 1.5 IPs for each MS-MS product ion measured, plus 1 IP for the precursor ion 
(whether measured or not). Thus, the described method, which measures 3 product ions 
scores 4.5 IPs, plus 1 IP for the precursor ion at m/z 175, yields a total of 5.5 IPs.
This more than fulfils the minimum identification criteria required for the method. 
However, for unambiguous identification, not only do the required number of ions have to 
be present, but all measured ion ratios in unknown samples must correspond to those in 
standards within predefined limits (see Chapter 1.11.1.). The maximum permitted 
tolerance in the ion ratio varies with the relative intensity of the product ions to the base 
peak. In LC-MS-MS, the maximum permitted tolerances are summarised in Table 1.1. In 
the method 2 ion ratios were measured for the purposes of analyte identification {m/z 102 : 
129 and 75 : 129), all of which had to meet these pre-set tolerances before they were 
considered acceptable. All of the samples used in the validation study met the relevant 
identification criteria.
3.3.2. Method performance characteristics
The described method is much easier to perform than the standard method described by 
(Lynch and Bartolucci, 1982). In our experience, a skilled analyst could process 4 samples 













































The extraction method was developed by improving, updating and modifying several 
published techniques (Lauridsen et al, 1988; Lynch and Bartolucci, 1982; Rose et al, 
1995, Van Ginkel et al, 1990). This simplified the method speeding up the extraction 
process, and also allowed the inclusion of automated solid phase extraction which 
increased the number of samples that could be analysed per run. The described method has 
the major advantage of being capable of handling 16 samples in duplicate in 1.5 days 
(again, excluding control samples). Fig 3.2. shows MRM chromatograms for a QCA 
standard (30 pg kg'1), a negative liver and a negative liver fortified with QCA at 3.0 pg 
kg 'at m/z 129, 102, 75 and 106 (internal standard, d4-QCA). The chromatograms show no 
spurious peaks due to the matrix. The negative meal is free of interfering peaks at the 
retention times of the analytes and only shows baseline signal over the time window, 
proving they are truly negative.
The absolute recovery (based on the analysis of 4 negative liver samples fortified with 
QCA at 30 pg kg'1 and carried through the method in the absence of internal standard) 
achieved by the described method (57.6 ± 5.1%) is comparable with the figure achieved 
by the GC-MS method (63.2 ± 4.8%). The accuracy and precision of the method was 
determined over a wide concentration range (3.0 - 300 pg kg'1) on three separate 
occasions to reflect the QCA concentrations that we have encountered in our statutory 
control schemes. Over this concentration range, a linear relationship between signal (ratio 
of transition m/z 175 —» 129 to transition m/z 179 -» 106) and QCA concentration (r2 = 
0.9°94) was observed. All results were calculated after the application of the identification 
criteria described in Chapter 1.11.1. These results are summarised in Table 3.1.
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The method adopted in this laboratory for the calculation of the limits of detection, CCa
and CCp is discussed separately in Chapter 1.11.5. and Chapter 1.11.6., respectively. For 
unauthorised compounds, the analytical limits may be determined graphically following 
the replicate analysis (n = 6) of blank samples fortified at 1.0, 1.5 and 2.0 times the 
MRPL. The MRPL is a limit established by the EC and CRTs. It is designed to harmonise 
the analytical performance of methods for authorised substances across Member States. 
Although an MRPL for QCA has not yet been set, it is likely that it will be one fifth of the 
former MRL for QCA (30 pg kg"1). We have chosen to assess CCa and CCP using a 
lower MRPL (2.0 pg kg'1) to ensure that our QCA method will meet the level finally 
adopted within the EU. Therefore, 6 known negative liver samples were fortified with 
QCA at 2.0, 3.0 and 4.0 pg kg'1. The samples were analysed using the described method 
and the relevant identification criteria were applied.
A graph of signal (m/z 129 : 106) versus added QCA concentration was constructed (Fig 
3.4). CCa was calculated as the concentration corresponding to the signal at the Y 
intercept plus 2.33 times the standard error of the Y intercept (a = 1%). A further 1.64 
times the standard errors of the Y intercept was added to the signal at the Y intercept to 
calculate the CCp.
In this way, the CCa, the Decision Limit was found to be 0.16 pg kg'1. This is the lowest 
concentration that can be distinguished from zero, with an error probability of 0.01. CCp, 
the detection capability, being the point at which 95% of samples will be declared 
violative with a P-error probability of 0.05 and a very low a-error probability, was found 


























Table 3.1. Accuracy and precision of LC-MS-MS method for QCA in fortified porcine liver.
3.0 ng kg 1 10 (xg kg'1 30 ng kg ' 100 |ig kg' 300 |ug kg'
Day 1
Mean 3.3 10.0 31.0 98.1 274
s 0.12 1.00 0.44 3.41 3.4
RSD 3.6 1.4 1.4 3.5 1.2
% Recovery 108 103 103 98 91
n 6 6 6 6 6
Day 2
Mean 3.2 10.3 29.2 88.9 268
s 0.22 0.38 0.68 3.25 10.3
RSD 7.0 3.7 2.3 3.7 3.9
% Recovery 107 103 97 89 89
n 6 6 6 6 6
Day 3
Mean 3.3 10.4 29.5 89.3 270
s 0.15 0.38 0.65 1.83 5.6
RSD 4.4 3.6 2.2 2.0 2.1
% Recovery 111 104 98 89 90
n 6 6 6 6 6
Overall
Mean 3.3 10.2 29.9 92.1 271
s 0.17 0.64 0.98 5.13 7.1
RSD 5.1 6.3 3.3 5.6 2.6
% Recovery 109 102 100 92 90
n 18 18 18 18 18
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3.3.3. Correlation of the described method with the standard gas chromatography 
MS method
Sixteen porcine liver samples, which contained incurred QCA residues at concentrations 
between 6.5 and 213.0 pg kg'1, were selected for analysis using both the GC-MS method 
and the described method. All of the samples had been collected as part of the statutory 
residues control schemes in NI. Fig 3.5. shows that the correlation (r2=0.9799) between 
the two methods was excellent, confirming the value of the LC-MS-MS method.
3.4. Conclusion
None of the previously published methods for QCA meets the new EC technical criteria 
for unambiguous confirmation of QCA in tissue, particularly those related to the 
identification of QCA residues to prevent false positive results. Furthermore, the existing 
methods are slow, cumbersome and are not applicable to large numbers of samples. We 
have developed a robust method for the unambiguous confirmation of QCA in porcine 
tissue. The method has been rigorously validated according to EU Commission Decision 
2002/657/EC for use in NI residue control schemes over a relevant concentration range 
(3.0 - 300 pg kg1). The linearity of the method has been demonstrated over this 
concentration range. The performance characteristics CCa and CCP have been calculated 
at 0.16 and 0.27 pg kg1, respectively and the method has been shown to correlate well 
with the previous in-house GC-MS method.. These show that the described method, which 
is rapid and capable of handling larger numbers of samples than the classical GC-MS 
method, is fit for purpose. The method has been routinely applied to the analysis of 
samples taken in NI under the UK National Surveillance Scheme. The objectives set for 
this chapter have therefore been fulfilled.
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3.5. Publications
The method described in this chapter was published in the Analyst in 2002:
Hutchinson, M. J., Young, P. Y., Hewitt, S. A., Faulkner, D., and Kennedy, D. G.,
2002, Development and validation of an improved method for confirmation of the 
carbadox metabolite, quinoxaline-2-carboxylic acid, in porcine liver using LC- 




Quinoxaline-2-carboxylic acid in pigs: criteria to distinguish 




The objectives of the work presented in this chapter were:
A) To investigate if the CBX metabolite, QCA, can be transferred from a group of 
medicated animals to a group of unmedicated animals through the use of the same 
housing, leading to a ‘violative’ laboratory result, as previously demonstrated with the 
antimicrobial furazolidone by this laboratory (McCraacken et al, 2000).
(B) If such transfer occurs, to investigate possible ways of differentiating between residues 
generated due to contamination of the housing and deliberate medication of the animals.
CBX was approved for use as a zootechnical feed additive in the EU, under Council 
Directive 70/524/EEC in 1974. Over the next 25 years concerns regarding the potential 
safety of the consumer, the animals and users (operators) were expressed leading the EU 
to withdraw all marketing authorisations for this compound in 1998. Consequently, there 
is effectively a zero tolerance for CBX-related residues in food of animal origin. QCA is 
the most persistent metabolite of CBX and has been designated as the marker residue for 
CBX use. National Surveillance Schemes for veterinary drug residues are required to 
monitor for the use of CBX in animals for human consumption. The unequivocal 
confirmation of the presence of any CBX-related residues should lead to exclusion of 
affected animals from the human food chain and possible prosecution of the producer in a 
court of law. However, veterinary drug residues can occur in animals by mechanisms 
other than deliberate administration. Accidental contamination of animal feeds, as a result 
of carry-over of medication during the feed milling process from medicated batches of 
feed to subsequent, ostensibly unmedicated batches of feed has been shown to has been 
shown to cause a variety of residue problems (see Chapter 1.4.3.) However, this should
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not occur with unauthorised compounds, as the feed mills will not have any of these 
compounds on site. Transfer of drugs may also occur from animal to animal via the 
passive transfer/ingestion of urine and/or faeces. Even brief exposure to the excretions of 
previously medicated animals (to mimic transportation to and within lairage of slaughter 
facilities) has been shown to result in violative residue levels in unmedicated animals 
(McCracken et al., 2000). This could lead to a producer, whose animals have tested 
positive for an unauthorised substance and whose animals have correctly been excluded 
from the human food chain being subjected to further legal proceedings. This leads to the 
possibility that one producer, presenting contaminated animals, could be further penalised 
in court as a result of abuse by another producer.
It may therefore be important for National Authorities to have criteria that can assist in the 
discrimination between contamination and illegal use. Previous work has shown that the 
use of the ratio concentrations of a compound in both tissue and bodily fluids can be 
successfully applied to differentiate between these possibilities (McCracken et al., 2000). 
In such cases of contamination, though it would be appropriate to exclude the carcasses 
from the human food chain, it would not be necessary to penalise the producer for any 
offence. The objective of the study was to see if the use of CBX could result in carryover 
of QCA from treated to untreated pigs. Also if it was subsequently possible to differentiate 
between environmental contamination and deliberate use by comparison of QCA 
concentration ratios between body fluids and tissues.
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4.2. Experimental
4.2.1 Experiment 1: Depletion of carbadox from pigs
This experiment was carried out to determine the concentrations of QCA in liver, kidney, 
muscle, urine, and bile in pigs fed CBX at therapeutic levels and then withdrawn from the 
drug over a period of two weeks. Twenty pigs were kept in a concrete floored house with 
ad libitum access to fresh water. Once a day they were fed a standard pig ration containing 
the equivalent to 50 mg kg'1 CBX (ICN Biomedicals, Oxfordshire, UK) at a rate of 1.0 kg 
per pig per day over 7 days. After the dosing period, the medicated animals were 
transferred into clean housing and fed unmedicated rations at the rate of 1.0 kg per pig per 
day for the remainder of the experiment. On day 0, 4, 7, 11, and 14 post-transfer, four pigs 
were removed and sacrificed. A further four pigs were killed at the start of the experiment 
to act as untreated controls. During necropsy, samples of liver (without biliary sack), 
kidney, muscle, urine and bile were taken. All samples were stored at -20°C prior to 
analysis.
4.2.2. Experiment 2: Exposure of untreated pigs to carbadox-contaminated housing
This experiment was carried out to compare the concentration of QCA in liver, kidney, 
muscle, urine and bile of animals exposed to housing contaminated with CBX. The house 
used for medicating the pigs in Experiment 1 was used as the source of contaminated 
housing. Following removal of the treated pigs, excess feed along with all faeces and urine 
was removed by scraping the floor of the house. Thereafter, twenty untreated pigs were 
transferred into the house. Feed and clean water was available to the pigs at all times. 
Directly after transfer and at 2, 4, 8 and 24 hours thereafter, 4 pigs were removed and 
sacrificed. This exceeds any expect exposure time that a group of animals is likely to
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experience through transport to, holding and slaughter. At necropsy, samples were 
removed and stored as in Experiment 1.
4.2.3. Determination of quinoxaline carboxylic acid concentrations in liver, kidney, 
muscle, urine, and bile.
Tlie method for the detection of QCA in porcine tissues has been described previously (see 
Section 3.2.). Briefly, each sample was minced and aliquots (5.0 g for solid tissues or 5 ml 
for fluids) taken for analysis. Deuterated internal standard (di-QCA, RIVM, Bilthoven, 
The Netherlands) was added to each at a concentration of 30 pg kg'1. Samples were 
hydrolysed in sodium hydroxide (3 mol f1), acidified and extracted with ethyl acetate. 
QCA was then back-extracted into phosphate buffer (0.1 mol l'1) at pH 8.0. Sample clean 
up was performed using automated solid phase extraction (SPE), the eluate being acidified 
and extracted again with ethyl acetate. All extracts were dried down under a stream of 
nitrogen and resuspended in methanol-water solution (10 : 90 v/v). QCA in the samples 
was detected and quantified using EC electrospray MS-MS. This was done by monitoring 
for transition products derived from the [M+H]+ ion of QCA at m/z 129, 102 and 75, and 
for the transition product derived from the [M+H]+ ion of cU-QCA at m/z 106. All data 
have been corrected for analytical recovery, as measured by isotope dilution of di-QCA, 




4.3.1. Experiment 1: Depletion of carbadox from pigs
QCA was not detected in any tissues or fluids taken from the pre-experimental control 
animals. The depletion of QCA residues in kidney, liver, muscle, bile and urine of pigs fed 
a therapeutic dose of CBX for 7 days is shown in Fig. 4.1. The QCA concentration was 
highest in urine before withdrawal at 147.9 ± 64.4 pg kg'1 and lowest in muscle (none 
detected). The QCA concentration in urine, bile, and kidney fell sharply over the 2 week 
withdrawal period to levels < 2 pg kg'1. Liver concentrations however declined less 
rapidly and were still easily detectable after 2 weeks at concentrations well in excess of 
the limit of quantification (LoQ) of the assay at 13.5 ± 2.5 pg kg'1.
4.3.2. Experiment 2: Exposure of untreated pigs to carbadox-contaminated housing.
Within 2 hours of being exposed to contaminated housing, the unmedicated pigs showed 
detectable concentrations of QCA residues in liver, kidney, bile, and urine (see Fig. 4.2.).
The highest concentrations were observed in urine at (38.5 ±3.1 pg kg'1) and the lowest in 
liver (0.8 ±0.1 pg kg'1). At the end of the 24 hour exposure period, the highest 
concentrations were again observed in urine (317.2 ± 115.8 pg kg'1) and the lowest in 
muscle at 0.5 ± 0.3 pg kg'1). Though fluid QCA concentrations increased throughout the 
exposure period, tissue QCA concentrations remained low. The highest were observed in 
kidney at 12.1 ± 1.6 pg kg"1 after 24 hours exposure. The ranking order (descending) of 
QCA concentrations was urine > bile > kidney > liver > muscle over the course of the 
experiment.
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4.3.3. Urine : liver quinoxaline carboxylic acid concentration ratio
Pigs treated with CBX and killed without any withdrawal (Experiment 1), had a mean 
urine : liver QCA ratio of 2.62 ± 2.4 (see Fig. 4.3. B). This ratio fell rapidly over the next 
7 days to a mean urine : liver QCA ratio of 0.19 ± 0.24, where it remained for the rest of 
the withdrawal period. The overall mean QCA urine : liver ratio for pigs subjected to any 
form of withdrawal (i.e. day 4 to day 14) was 0.31 ± 0.27.
After only 2 hours exposure to contaminated housing, the unmedicated pigs (Experiment 
2) had a mean urine : liver QCA ratio of 40.61 ± 13.11 (see Fig. 4.3. A). The mean urine : 
liver QCA ratio varied over the hour exposure period but was lowest after 24 hours with a 
mean urine : liver QCA ratio of 10.59 ± 7.74. The overall mean QCA urine : liver ratio 
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Fig. 4.1. Concentrations of QCA in liver, kidney, muscle, bile and urine for pigs treated with CBX in 

























Fig. 4.2. Concentrations of QCA in liver, kidney, muscle, bile and urine for previously unmedicated 
pigs exposed to housing vacated by CBX treated pigs over a 24 hour period.
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4.4. Discussion
Under EU National Surveillance Schemes, detection of any quantity of QCA in a liver 
sample is a non-compliant result. Commission Regulation EC 2788/98 prohibits the use of 
CBX in food-producing animals. Previous studies with another unauthorised drug, 
furazolidone, have shown that it can be transferred from pig-to-pig through even brief 
contact with accommodation that previously had housed medicated animals. It is desirable 
therefore to know whether or not it is possible that a non-compliant QCA result could be a 
result of contact with the urine or faeces of illegally medicated animals, rather than 
deliberate medication. Additionally, it is desirable to have criteria by which it can be 
determined whether a non-compliant laboratory result for QCA indicates deliberate abuse 
or accidental contamination. In order to determine criteria for such a differentiation, the 
tissues and fluids that were removed from the carcass after sacrifice are all readily 
accessible for sampling in any commercial processing plant.
4.4.1. QCA in pigs exposed to environmental contamination.
QCA residues are present at detectable levels after 2 hours exposure to a contaminated 
environment in four of the five tissues taken (see Fig. 4.2.), showing that QCA, as well as 
being picked up by clean unmedicated pigs, is rapidly absorbed and may be detected in 
tissues and fluids after short exposure periods. Even such short exposure (2 hours) to a 
contaminated environment could therefore potentially lead to a non-compliant result in 
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4.4.2. Possible criteria for distinguishing between abuse and contamination.
The mean urine : liver QCA concentration ratio in animals subjected to medication with 
CBX and to any form of withdrawal (see Fig. 4.3 B) was 0.56 ± 0.21 (no values greater 
than 0.8). The mean urine : liver QCA concentration in unmedicated animals, exposed to 
contaminated housing (see Fig. 4.3 A) was 10.59 ± 7.74 (no values less than 4.5). These 
figures suggest that it may therefore be possible to differentiate between environmental 
contamination and deliberate medication on the basis on the urine : liver QCA 
concentration ratio.
The pharmacokinetics of CBX can be used to explain the difference in these ratios. In an 
animal subject to medication, the administered CBX undergoes metabolism in the liver to 
QCA, the liver acts as a ‘trap’ for QCA and it is slowly removed (over several weeks) 
from this tissue mainly via bilary excretion. Thus in a deliberately medicated animal, liver 
concentrations of QCA are high, with lower concentrations in the urine, leading to a low 
urine : liver ratio. However in a situation where contamination occurs CBX is being 
passed into the animals system in its already metabolised state as QCA, and therefore does 
not need to undergo liver metabolism (and is thus not trapped) and can be directly 
excreted via the kidneys. Therefore in a directly contaminated animal the liver 
concentrations of QCA are low, with higher urine concentrations leading to a higher urine 
: liver ratio.
4.4.3. Implications of this study
On the basis of the above results, animals treated with CBX and subject to any withdrawal 
period would have a urine : liver QCA concentration of less than 0.80, whereas animals
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exposed to environmental contamination with CBX would have a urine : liver QCA 
concentration of greater than 4.5. Any samples falling within the range 0.9 - 4.4 should be 
therefore considered as inconclusive and be the subject of intensive investigation. Though 
these are only tentative criteria, based on a small number of animals, they might form the 
basis of a means of discrimination, whereby competent National Authorities could decide 
between an offence resulting from deliberate abuse of CBX, and/or exposure of pigs, 
belonging to an innocent producer, to an environment which had previously contained 
illegally medicated animals. These criteria are drawn from a small number of samples and 
may be more accurately redefined by analysis of a larger population.
4.5. Conclusions
Under the EU National Surveillance Schemes, detection of any quantity of QCA in a liver 
sample constitutes the offence of use of CBX. Previous studies however have shown that 
drugs can be transferred from pig-to-pig through brief contact with lairage that previously 
has housed medicated animals. It is desirable therefore to have knowledge of whether it is 
possible that a violative QCA result could be due to contact with the urine or faeces of 
illegally medicated animals, rather than deliberate medication. The studies presented in 
this chapter show that a violative QCA result can be due to exposure to a QCA 
contaminated environment. It is also desirable to have criteria by which it can be 
determined whether a positive laboratory test for QCA has been due to deliberate abuse, or 
as the result of this contact.
The studies presented put forward tentative criteria for the differentiation between 
exposure to a contaminated environment and deliberate abuse. For ease of laboratory 
determination, all the tissues and fluids that were removed from the carcass after sacrifice
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are all readily accessible for sampling in any commercial processing plant. Thus, assisting 
competent national authorities to easily set up a testing program to determine whether a 
positive result for QCA in porcine tissue is truly ‘violative’. The objectives set for this 
chapter have therefore been fulfilled.
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4.6. Publications
The work presented in this chapter was accepted by Food Additives and Contaminants in 
2004 under the title:
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., Quinoxaline-2-carboxylic acid in 
pigs: criteria to distinguish between illegal use of CBX and environmental contamination.
The results described in this chapter were presented in poster format at the Fourth 
International Symposium on Hormone and Veterinary Drug Analysis, Antwerp, Belgium 
in 2002 under the same title.
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Chapter 5
Simultaneous determination of the carbadox metabolite, 
quinoxaline-2-carboxylic acid and the olaquindox metabolite, 
methyl-3-quinoxaline-2-carboxylic acid in porcine liver using 
liquid chromatography electrospray tandem mass spectrometry
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5.1. Introduction
The objectives of the work presented in this chapter were:
(A) To develop a fast and robust confirmatory method for the OQX marker residue in 
porcine tissue, MQCA, due to the prohibition of the use of OQX in livestock farming.
(B) To validate the developed method as defined by regulations for EU analytical method 
validation as laid out in EU Commission Decision 2002/657/EC, so the method may be 
applied to the statutory testing of samples in NI taken under the UK National Surveillance 
Scheme and Meat Inspection Scheme complying with EU Council Directive 96/23/EC.
OQX is rapidly metabolised in animal tissue via mono and desoxy compounds to MQCA. 
This is the longest existing detectable metabolite found in tissue and therefore designated 
as the marker residue for OQX use in animals by the EU. No methods have been described 
to date for the analysis / conformation of MQCA, only for the detection of OQX or its 
related desoxy metabolites in tissue. A sensitive method for the extraction and analysis of 
MQCA residues in animals of food origin was required by the EU. Due to the similarity in 
chemical structure, the tissue extraction and analysis procedure developed for QCA (see 
Chapter 3.2.3.) was modified for the dual confirmation of the compounds. We aimed to 
produce a validated method that could readily confirm QCA and MQCA at concentrations 
below any anticipated future MRPL that would be set by the European Commission. 
Samples were then analysed using HPLC linked via electrospray interface to tandem MS 
in positive mode. The EU has revised the criteria that must be applied in both the 
screening and confirmation of veterinary drug residues in animals of food origin, replacing 
those previously used. This chapter describes a method for the confirmation of the CBX 
metabolite, QCA, and the OQX metabolite, MQCA, in porcine liver (the target organ for
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analysis) that meets all these new technical criteria. The described method offers a 
considerable advantage in terms of turnaround time over previously published methods in 
the numbers of samples that can be processed by a skilled analyst per batch. The accuracy 
and precision of the method were assessed over a wide concentration range (3-150 pg 
kg"1) to reflect a likely range of naturally incurred samples.
5.2. Experimental
5.2.1. Materials
All solvents were of HPLC grade and all other chemicals were of analytical reagent grade. 
Distilled or de-ionised water was used throughout the study. A deuterium labelled form of 
Quinoxaline-2-Carboxylic Acid (drQCA) was obtained from RIVM (European Union 
Reference Laboratory, Bilthoven, The Netherlands) and QCA was obtained from Sigma- 
Aldritch Co. Ltd (Gillingham, Dorset, UK.). A deuterium labelled form of Methyl-3- 
Quinoxaline-2-Carboxylic Acid (d7-MQCA) was custom synthesised by CSS (Craigavon, 
Antrim, UK) and MQCA was custom synthesised by QuChem (Queen’s University, 
Belfast, UK.). Stock standard solutions of MQCA (1.0 mg ml'1), dy-MQCA (1.0 mg ml'1), 
QCA (1.0 mg ml1) and d4-QCA (10.0 pg ml1) were prepared by dissolving each in 
methanol. Working standards (1.0 pg ml1) of all solutions were prepared by serial 
dilutions of the stock standards in methanol. Stock standards were stable for 1 year and 
working standards were stable for at least 3 months when stored in amber vials below 4 
°C.
Protease Type XIV for enzymatic digestion was obtained from Sigma-Aldritch Co. Ltd 
(Gillingham, Dorset, UK.). Solutions of protease were prepared in water (50 mg ml'1) and
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remade each day, when required. The enzyme digest solution was a buffer solution made 
up of 0.2 M Tris(hydoxymethyl)methylamine and 0.1 M calcium chloride at pH 9.6 
(TRIS/CaCl buffer). The back extraction solution was 0.1 M sodium phosphate buffer, pH 
8.0. Mobile phase A (A) contained methanol-acetonitrile-water-acetic acid (10 : 10: 79.6 : 




Tandem MS analyses were performed using a Quattro LC (Micromass, Wythenshawe, 
UK) in positive mode. A Hewlett Packard (Stockport, Cheshire, UK) HPLC system 
comprising an 1100 Series binary pump, autosampler and solvent degasser were coupled 
via electrospray interface to the Quattro LC. Two Luna 3p Cig 150 X 2.0 mm 
(Phenomenex, Macclesfield, Cheshire, UK) LC columns were used each with a Sp 2.0 mm 
Cis guard column (Phenomenex, Macclesfield, Cheshire, UK) attached. The MS source 
was maintained at 150 °C with nitrogen used as the drying and nebulising gas at a flow 
rate of 600 and 80 1 h’1, respectively. The sample volume injected was 15 pi and the total 
run time was 20 min. The mobile phase flow rate was 0.2 ml min'1 with all the column 
effluent entering the mass spectrometer.
Before beginning analysis, both columns were equilibrated by pumping mobile phase at 
pre-run conditions for 30 - 45 min. A gradient programme was run for each sample, the 
pre-run conditions were 100 : 0 (mobile phase A : B). After 1 min, this was ramped to 20 : 
80 (mobile phase A : B) over 9 min and then held until 15 min when the mobile phase was 
returned to pre-run conditions 100 : 0 (mobile phase A : B) over 0.5 min and held there
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until the end of the run at 20 min. Each column was attached to the MS system via a 
switch valve (Prolab, England, UK), while one column was in use its companion was re­
equilibrated to pre-run mobile phase conditions.
5.2.3. Sample Extraction
Aliquots of homogenised test or control liver (5.00 ± 0.05 g) were weighed into 
polyethylene tubes (50 ml). Two known negative samples were analysed in every batch. In 
addition, four recovery samples, fortified at 10.0 pg kg'1 were prepared by the addition of 
both QCA and MQCA working standard solution (50 pi) to known negative tissue. A 
further two check samples were analysed with every batch. These were known negative 
samples that had been fortified with QCA and MQCA at concentrations unknown to the 
analyst. Fortified samples for validation purposes were also prepared at this stage by 
addition of the relevant amount of QCA or MQCA standard solutions. Internal standards, 
cLrQCA and dv-MQCA (50 pi of the 1.0 pg ml'1 working standards) were added to every 
sample to be analysed. To all samples TRIS/CaCl buffer (9 ml) and protease solution (50 
pi, 50 mg ml1) was added, the contents mixed for 30 sec., and incubated at 55 °C 
overnight. Samples were removed and allowed to cool to room temperature and then 
centrifuged (2000g, 4 °C, 5 min.). The supernatant was poured off and to this concentrated 
hydrochloric acid (1 ml) added. The subsequent ethyl acetate extraction, phosphate buffer 
extraction, SPE and further ethyl acetate extraction of QCA and MQCA from tissue matrix 
are identical to those in the QCA extraction method stated in Chapter 3 from this stage 
onwards (see Chapter 3.2.3.). The extraction steps are outlined briefly below.
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Ethyl acetate (6 ml) was added and tubes shaken and centrifuged (2,000g, 4 °C, 10 min.) 
The upper layer was transferred into a polyethylene tube (50 ml) and the extraction 
repeated. Back extraction solution (0.1 mol f1, pH 8.0, 8 ml) was added to the extract, the 
tubes shaken and centrifuged (2000g, 4 °C, 10 min.). The upper organic layer was 
aspirated to waste and an aliquot (4 ml) of the aqueous phase transferred to a 10 ml glass 
tube containing concentrated hydrochloric acid (1 ml). The SPE was carried out on an 
ASPEC XL4 coupled to a 404-syringe pump (Gilson Ltd, Middleton, Wisconsin, USA) 
using non-endcapped benzenesulphonic acid (SCX), 1 g sorbent material, 3 ml capacity, 
disposable solid phase extraction cartridges (1ST Ltd, Mid. Glamorgan, UK). Each eluted 
sample was acidified with concentrated hydrochloric acid (300 pi). Ethyl acetate (2 ml) 
added, the tubes mixed and centrifuged (2000#, 4 °C, 10 min.). The upper organic layer 
was transferred into 6 ml tubes. The extraction was repeated a further two times with the 
extracts being combined. The sample extracts were taken to dryness under a stream of 
nitrogen at 60 °C, methanol-water solution (10 : 90 v/v, 100 pi) added and tube vortexed 
for 15 sec.
Standards were prepared at 10 pg kg"1 by the addition of QCA, MQCA, drQCA and d?- 
MQCA working standards (10 pi, 1 pg mf1) to 3 ml glass tubes and taken to dryness 
under nitrogen. Methanol-water solution (10 : 90 v/v, 100 pi) was added and the tube 
vortexed. All the solutions were then transferred to tapered microvials for analysis.
5.2.4. LC-MS-MS analysis
Spectra for MQCA and D4-MQCA were obtained over the range m/z 50-200 with the 
instrument configured for MS only; spectra for QCA and cb-QCA have been previously
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shown in Chapter 3.3.1. Multiple reaction monitoring (MRM) was set for the detection of 
QCA, cU-QCA, MQCA, and dv-MQCA. Quadrupole 1 was set to transmit the molecular 
ions ([M + Hf) of QCA (m/z 175), d4-QCA {m/z 179), MQCA (m/z 189) and d7-MQCA 
(m/z 196). Quadrupole 2 was set to transmit the QCA product ions at m/z 102 and 75, the 
MQCA product ions at m/z 145 and 102 along with the internal standard product ions for 
dt-QCA and d7-MQCA at m/z 106 and 152, respectively. Argon was used as the collision 
gas and was bled into the cell at a pressure of 2.3 x 10"3 mbar. The collision cell entrance 
and exit energies were set at 0 and 2 eV, respectively. The collision energy for the QCA 
product ions at m/z 102 and 75 were optimised at 30 and 45 eV, respectively. The collision 
energy for the MQCA product ions at m/z 145 and 102 were optimised at 16 and 34 eV, 
respectively. The internal standard product ions for dt-QCA (m/z 106) and d7-MQCA (m/z 
152) were optimised at 30 and 16 eV, respectively. The cone voltages for QCA and 
MQCA were 30 and 20 V, respectively, and the dwell time for each ion was 0.5 sec.
Concentrations for QCA were calculated by comparing the ratio of the m/z 175 —> m/z 102 
(QCA base peak) response with the m/z 179 —>• m/z 106 response (dj-QCA) in the sample 
with those in the standards (10.0 pg kg'1) within the run. Concentrations for MQCA were 
calculated by comparing the ratio of the m/z 189 -> m/z 102 (MQCA base peak) response 
with the m/z 196 —> m/z 152 response (d7-MQCA) in the sample with those in the 
standards (10.0 pg kg'1) within the run.
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5.3. Results and discussion
5.3.1. Tandem MS analysis of quinoxaline carboxylic acid and methyl quinoxaline 
carboxylic acid
The fragmentation pattern of QCA has already been described in Chapter 3 (see Fig 3.1.). 
The MS-MS of the molecular ion of QCA (m/z 175) produces a prominent product ion at 
m/z 129. This results from the successive loss of water and carbon monoxide supported by 
the observation of a small peak at m/z 157 - the loss of H2O. Similarly, the MS-MS of the 
molecular ion of MQCA (m/z 189) also produces a prominent product ion resulting from 
the successive loss of water and carbon monoxide (m/z 145). This again is supported by 
the observation of a small peak (m/z 171) resulting from the loss of H2O (see Fig. 5.1.). An 
identical product ion for QCA and MQCA is formed at m/z 102, in the case of QCA it is 
due to the loss of HCN from the m/z 129 product. For MQCA it is due to the loss from the 
m/z 145 product ion of a methyl group (CH3) followed by HCN. QCA produces another 
prominent product ion at m/z 75; this can be attributed to the successive loss of another 
HCN from the m/z 102 product. MQCA shows a similar loss of HCN that is supported by 
the observation of a prominent peak at m/z 75.
According to draft technical criteria for residue identification in food of animal origin, a 
maximum of 4 identification points (IPs) are required to confirm unauthorised substances 
(see Chapter 1.11.). The criteria score 1.5 IPs for each tandem MS product ion measured, 
plus 1 IP for the precursor ion whether it is measured or not. The described method scores 
4 IPs for both QCA and MQCA through the measurement of two product ions (plus one 
precursor ion). Both thus fulfil the identification criteria. However, for unambiguous 
identification the ion ratios of unknown samples have also to correspond to those in the 






































The tolerances allowed for the ion ratios vary relative to the intensity of the product ion to 
the base peak ion. For QCA the ion ratio of m/z 75 : 102 was measured and for MQCA the 
ion ratio of m/z 102 : 145 was measured. These ratios had to meet the previously 
mentioned pre-set tolerances before they were considered acceptable All results were 
calculated by comparison of the ratio of the analyte response to the equivalent internal 
standard response in the sample with those in the bracketed standards (10.0 pg kg'1) within 
the run.
5.3.2. Method performance characteristics
The extraction method differs from that described in Chapter 3. To allow the inclusion of 
the deuterated internal standard for MQCA (dy-MQCA), it was necessary to remove the 
sodium hydroxide hydrolysis step and replace it with a protease digest as used by Van 
Ginkel et al. (1995). The rest of the extraction technique remained the same; this had the 
major advantage of permitting the processing of 16 samples in duplicate (excluding 
negatives, controls and check samples) in 1.5 days by a skilled analyst. Modification of 
this method now allows the extraction and analysis of MQCA as well as QCA using this 
fast and robust procedure.
The absolute recovery (that is based on the analysis of 4 negative liver samples fortified 
with both QCA and MQCA at 10 pg kg'1 and carried though the method in the absence of 
internal standard) achieved by the described method is 54.2 ± 0.9 % (Mean ± s, n = 4) and 
48.0 ± 2.9 % (Mean ± s, n = 4) for QCA and MQCA, respectively. The recovery achieved 
for analysis of QCA using the reported dual method is comparable to the value previously 
obtained for the singular analysis of QCA (57.6 ± 5.1 %). Fig. 5.2. shows MRM 























































































































































































































































fortified with QCA at 3.0 fig kg'1 at m/z 102, 75 and 106 (internal standard). Fig. 5.3. 
shows MRM chromatograms for a MQCA standard (10 jag kg'1), a negative liver and a 
negative liver fortified with MQCA at 3.0 gg kg'1 at m/z 145, 102 and 152 (internal 
standard). Both sets of chromatograms showed no spurious peaks due to the matrix. The 
negative samples for both sets of chromatograms show only the internal standard peak 
{m/z 106 and 152, QCA an MQCA, respectively) with only background noise spectra 
present for each of the other ions monitored. Thus showing the blank samples are truly 
negative.
The accuracy and precision of the method was determined over the concentration range 
(3.0 - 150 pg kg'1) on three separate occasions, which reflects QCA concentrations 
encountered in NI statutory control schemes, and also provides a wide concentration range 
over which to assess MQCA method performance (see Table 5.1. and Table 5.2.). Over 
the assessed concentration range, the results displayed the same satisfactory accuracy and 
precision as the previously published method. QCA shows over this concentration range a 
linear relationship between the signal (ratio of the transition m/z 175 -> 102 to transition 
m/z 179 —» 106) and fortified concentration (r2= 0.998) (Data not shown). The same linear 
relationship is also observed for MQCA between signal (ratio of transition m/z 189 -> 102 
to transition m/z 196 -» 152) and fortified concentration (r2= 0.952) (Data not shown).
The European Commission has set out new procedures for the determination of a 
confirmatory methods analytical limit. This involves the calculation of the Decision Limit 
and Detection Capability. The Decision Limit (CCa) is defined as the limit at which it can 
be decided that a result is violative with an error probability of a (a = 1% for unauthorised 
substances). The Detection Capability (CCP) is defined as the smallest concentration of
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analyte that can be identified and quantified in a sample with a statistical certainty of l-(3 
(P < 5% for unauthorised substances). CCa and CCp were calculated for both QCA and 
MQCA, each result having to fulfil all EU criteria for residue identification, before it 
could be considered for use. These analytical limits may be determined by the analysis of 
replicate blank samples (n = 6), fortified at 1.0, 1.5 and 2.0 times the minimum required 
performance limit (MRPL) - a limit established by the EU, designed to harmonise 
analytical methods for unauthorised substances in the EU. However, no MRPL for either 
QCA or MQCA has yet been set.
Therefore, we have chosen to assess CCa and CCP using a lower MRPL (2.0 pg kg'1) 
than that is expected to be set for either compound, to ensure that the method will meet the 
level finally adopted within the EU. Replicate fortified blank samples (n = 6) were 
prepared at 2.0, 3.0 and 4.0 pg kg'1 for QCA and MQCA. A graph of signal ratio (m/z 175 
-» 102 : m/z 179 -> 106 for QCA and m/z 189 -> 102 : m/z 179 -> 152 for MQCA) 
versus added concentration was constructed for both compounds. CCa was calculated as 
the concentration corresponding to the Y intercept plus 2.33 times the standard error of the 
Y intercept. CCp was calculated as the concentration corresponding to the Y intercept for 
CCa plus a further 1.64 times the standard error (see Fig. 5.4. and Fig. 5.5.). The Decision 
Limit (CCa), the lowest concentration that can be distinguished from zero with an a error 
probability of 0.01, was calculated at 0.34 pg kg'1 and 0.82 pg kg'1 for QCA and MQCA, 
respectively. The Detection Capability (CCP), the point where 95% of samples will be 
declared violative with a P error probability of 0.05, was calculated at 0.57 pg kg"1 and 
1.40 pg kg'1 for QCA and MQCA, respectively.
- 135 -
Table 5.1. Accuracy and precision of the LC-MS-MS method for QCA in fortified
porcine liver.
3.0 pg kg ' 10.0 pg kg'1 50 pg kg 1 150 pg kg1
Day 1
Mean 3.2 10.2 47.3 137.6
s 0.1 0.2 0.7 2.7
RSD 1.9 1.9 1.4 2.0
% Recovery 106.2 101.7 94.6 91.7
n 6 6 6 6
Day 2
Mean 3.2 10.7 50.1 143.4
s 0.3 0.4 2.4 4.1
RSD 10.0 4.1 4.2 2.1
% Recovery 107.9 106.7 100.3 95.6
n 6 6 6 6
Day 3
Mean 3.2 9.7 48.5 144.2
s 0.2 0.3 1.2 2.7
RSD 6.9 2.8 2.4 1.9
% Recovery 107.5 96.9 97.1 96.2
n 6 6 6 6
Overall
Mean 3.2 10.2 48.7 141.8
s 0.2 0.5 1.8 4.0
RSD 6.7 5.0 3.7 2.8
% Recovery 107.2 106.3 97.3 94.5
n 18 18 18 18
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Table 5.2. Accuracy and precision of the LC-MS-MS method for 1MQCA in fortified porcine liver.
3.0 jig kg'1 10.0 ng kg ' 50 ^g kg ' 150 jag kg '
Day 1
Mean 2.8 10.6 50.4 141.8
s 0.2 0.8 4.3 7.3
RSD 7.9 7.1 8.6 5.2
% Recovery 93.8 106.4 100.8 94.6
n 5 6 6 6
Day 2
Mean 3.6 10.8 51.2 144.4
s 0.3 0.5 2.6 3.9
RSD 8.9 5.1 5.2 2.7
% Recovery 119.7 108.3 102.4 96.3
n 6 6 6 6
Day 3
Mean 3.3 10.5 48.0 132.1
s 0.4 0.4 0.6 4.3
RSD 3.9 4.0 1.2 3.3
% Recovery 118.5 105.2 96.1 88.1
n 6 6 6 6
Overall
Mean 3.3 10.7 49.9 139.4
s 0.4 0.6 3.1 7.5
RSD 12.9 5.4 6.2 5.3
% Recovery 111.2 106.6 99.7 90.2
n 17 18 18 18
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To assess the ability of the method to work with possible field samples, incurred liver 
samples from pigs fed OQX medicated feed (10 pg kg'1, one tenth of the recommended 
prophylactic dose) for 4 days, were tested for the presense of MQCA. MQCA residues 
were detected at significant levels (~16 pg kg"1) by this method (data not shown).
5.4. Conclusions
A fast and robust method has been developed for the detection, confirmation, and 
quantification of both QCA and MQCA, the marker substances for the use of CBX and 
OQX, respectively, in porcine tissue. The method has been validated according to EU 
Commission Decision 2002/657/EC. All results before they are considered viable for use 
were assessed using new EU criteria for the unambiguous confirmation of prohibited 
substances. The linearity, accuracy and precision have been demonstrated over the 
concentration range 3.0 - 150 pg kg1, and the performance characteristics (CCa and 
CCP) have been calculated for the described method. Although an MRPL for QCA or 
MQCA has not yet been set, the method performance characteristics were assessed at a 
lower MRPL value (2.0 pg kg'1) than is expected to be set for both compounds, thus 
ensuring the method will meet any concentration finally adopted by the EU.
The method meets all EU criteria for method validation and is therefore suitable for use in 
the unambiguous confirmation of both QCA and MQCA in porcine tissue. This method 
has been routinely applied to the analysis of samples taken in NI under the UK National 
Surveillance Scheme. The objectives set for this chapter have therefore been fulfilled.
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5.5. Publications
The method presented in this chapter has been submitted to the Journal of Chromatograhy 
B in 2003 under the title:
Hutchinson, M. J., Young, P. B., and Kennedy, D. G., Development and validation of a 
dual method for the confirmation of quinoxaline-2-carboxylic acid (a metabolite of 
carbadox) and methyl-quinoxaline-2-carboxylic acid (a metabolite of olaquindox), in 






There is public concern that the widespread use of veterinary drugs in agricultural practice 
will give rise to the presence of harmful residues in animal tissues or products destined for 
human consumption. Acute cases of pharmacological toxicity due to (3-agonist drugs and 
(3-lactam antibiotics have been reported in Europe. Concerns have also been raised over 
the carcinogenic and genotoxic nature of some drugs and/or their metabolites commonly 
used in livestock and poultry production. Since the mid. 1970s, the Eli, in partnership 
with other trading blocks and unaffiliated countries, has introduced legislation governing 
the use of veterinary drugs and the monitoring of their residues. This is to guarantee the 
safety of the consumer as well as assuring the quality of imported and/or exported 
products. MRLs have been set for currently licensed drugs and zootechnical feed 
additives, with an effective ‘zero tolerance’ policy for residues of illegal drugs or 
compounds that have had their product licence withdrawn. Each Member State is required 
to set up its own National Surveillance Scheme to police these set MRLs and identify 
misuse. This requires the screening of thousands of samples per year with the subsequent 
confirmation of any samples suspected to be in breech of EU regulations. Ideally, all 
Member States should be able to test for all the licensed drugs and illegal substances laid 
out in EU legislation. Unfortunately, analytical methods for the confirmation of every drug 
currently used in modem veterinary medicine do not exist, thus, until such a time Member 
States should show that they have exercised ‘due diligence’. Confirmatory methods must 
be developed by NRLs and CRTs to comply with current legislation, conduct 
pharmacokinetic studies, and investigate persistent residue problems. Such methods 
should be based on molecular spectrometry as it allows unambiguous compound 
identification.
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The quinoxaline-N-dioxides, when administered as feed additives can significantly 
improve feed conversion efficiency and slaughter weight in pigs. They have also been 
found effective against a range of gram negative gastrointestinal infections. In the 1980s 
and 90s an increasing body of evidence suggested that such compounds were 
carcinogenic, mutagenic and in the case of some derivatives, highly phototoxic. This led to 
the prohibition of CBX and OQX as zootechnical feed additives in 1998 by the European 
Commission. Several methods are presented in this thesis for the unambiguous 
confirmation of the banned quinoxaline-N-dioxides, CBX, and OQX in animal 
feedingstuffs and in porcine tissue. Liquid chromatography linked via electrospray 
interface to tandem MS was used in the analysis of both compounds to provide the 
sensitivity and specificity needed to meet new EU legislation for the confirmation of 
veterinary drugs.
6.2. Confirmation of carbadox and olaquindox in feeds
Though CBX and OQX are prohibited within the EU, they are still licensed for use as feed 
additives in other non-EU countries and are available as premixed zootechnical feed 
products, thus, the potential still exists for illegal use of both drugs within Europe. It has 
been demonstrated that low concentrations of drugs can be carried over from one batch of 
medicated feed into several subsequent batches of unmedicated feed causing unwanted 
and illegal residue levels in tissue. A current requirement within the EU is for a 
confirmatory method capable of determining low concentrations of CBX and OQX in 
porcine animal feed, thus aiding the feed industry to spot sources of contamination and 
eliminate them, and allowing Member States to police the ban.
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The main objective of Chapter 2 was therefore to develop a dual confirmatory method for 
CBX and OQX in porcine feedingstuffs that met all current EU criteria for method 
validation. This method employs a simple chloroform-acetonitrile (50 : 50 v/v) extraction, 
with no additional clean-up to separate the analytes from the feed matrix. Matrix based 
standards are employed, with both samples and standards separated chromatographically 
via HPLC using an isocratic mobile phase of acetonitrile-water-formic acid (17.5 : 82.4 : 
0.1 v/v). The HPLC system is connected via electrospray interface to the MS where 
analysis is carried out by tandem MS in positive mode. The MS-MS of the CBX and OQX 
molecular ions [M + H]+ at m/z 263 and 264, respectively, produces daughter ions at m/z 
231 and 89 for CBX and m/z 212 and 143 for OQX. The base peak ion at m/z 231 and m/z 
212 for CBX and OQX, respectively, are used to calculate the concentrations of each drug 
in the sample by comparison to the same ion in the matrix standards within the run. The 
method was validated according to current EU criteria for confirmatory methods. The 
validation was carried out at 1 - 10% of the EU’s prior legal infeed concentration (0.5 - 
5.0 mg kg'1) to reflect the necessity of detecting possible contamination levels of the drug 
in compound feedingstuffs. The Limit of Determination for this method is 0.5 mg kg'1 as 
this is the lowest concentration at which the described method has been validated with a 
specified degree of accuracy and precision. The Detection Limit (based on a signal: noise 
ratio of 3 : 1) achievable by this method is approximately one order of magnitude lower 
for each compound (i.e. approximately 50 pg kg'1).
The method has been applied to the statutory testing of National Surveillance Scheme 
samples in NT
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In the future, this method could be applied to the study of possible carryover of both CBX 
and OQX into unmedicated feed. Such a study would allow National Authorities to be 
aware of possible contamination of unmedicated feedingstuffs with CBX or OQX, and 
subsequently the potential for causing accidental and/or unwarranted QCA residue levels 
in animals at slaughter.
6.3. Confirmation of quinoxaline carboxylic acid in tissue
Under EU legislation, Members States are required to analyse edible meat products for the 
presence of drug residues. In pigs, liver and gastrointestinal enzymes metabolise CBX to 
undetectable concentrations within a 24 to 48 hours of the cessation of medication. 
Therefore the metabolite, QCA, has been assigned the marker residue of CBX use in 
tissue, and is detectable in liver samples 6 weeks after the cessation of medication. There 
is a current requirement within the EU for a fast, robust, confirmatory method for QCA in 
porcine tissue that will meet all EU criteria for method validation.
The first objective of the work in Chapter 3 was to develop such a confirmatory method 
for QCA. An electrospray tandem MS method is described for QCA in porcine liver, with 
the use of a deuterated form of QCA (di-QCA) as an internal standard. This method 
involved the alkaline hydrolysis of the matrix followed by two liquid-liquid extractions. 
Interferants were separated from the analyte by use of automated cartridge based solid 
phase extraction. A further liquid-liquid extraction was applied to remove the analyte into 
an organic medium for subsequent sample concentration and preparation for HPLC. The 
HPLC system employing an isocratic mobile phase of methanol-water-acetic acid (40 : 
59.6 : 0.4 v/v), was connected via electrospray interface to the MS where the analytes 
were detected by tandem MS in positive mode. The molecular ion [M + H]+ of QCA {m/z
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175) produces three prominent products at m/z 129, 102 and 75. The daughter ion at m/z 
102 was used to calculate the QCA concentration in the sample by comparison to the 
internal standard (drQCA) ion, m/z 106, within the same sample and the standards. The 
method was validated according to current EU legislation over the concentration range 3.0 
- 300 pg kg"1 to reflect the spread of results in porcine liver gathered by the NI National 
Surveillance Scheme. The assessed detection parameters - CCa and CCP, were 0.16 and 
0.27 pg kg'1, respectively. These are lower than any estimated MRPL (~6.0 pg kg'1) that 
will be set by the EU.
The second objective of this chapter was to compare the developed method to the current 
in-house GC-MS method to assess its suitability and to guarantee the consistent accuracy 
of results. Both methods gave good agreement (r2=0.9799) over the wide range of 
concentrations measured (6.5 - 213 pg kg'1).
The fast and robust EC tandem MS method has been successfully applied to the statutory 
testing of National Surveillance Scheme samples in NI.
6.4. Bioavailability of quinoxaline carboxylic acid in pigs
Using the nitrofuran antibacterial, furazolidone, McCracken et al. (2000) demonstrated 
that even brief exposure to the excretions of previously medicated animals could result in 
violative residue levels in unmedicated animals. This leads to the possibility that one 
producer, presenting contaminated animals, could be penalised in court because of abuse 
by another. In order to aid National Authorities discriminate between such cases, 
pharmacokinetic studies were carried out to determine if the same violative residues levels
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could be seen through CBX medication of pigs and the subsequent contamination of 
housing.
The first objective of the work described in Chapter 4 was to establish if the metabolite of 
CBX, QCA, could be transferred from medicated to untreated animals through exposure to 
a contaminated environment. A group of pigs was fed CBX infeed (50 mg kg ') for seven 
days and then removed from their lairage. Clean untreated pigs were moved into the same 
housing after cleaning. Within 2 hours of being exposed to the housing, untreated pigs 
showed detectable concentrations (<2 pg kg'1) of QCA in liver, kidney, bile and urine 
samples, with significant levels after 24 hours of exposure. Thus, even a short exposure 
time (< 2 hours) could result in a possible ‘violative’ laboratory result for CBX use.
Having shown that such transfer is possible, the second objective of chapter 4 was to 
determine if it was possible to differentiate in the laboratory, between animals subject to 
deliberate medication and those exposed to a contaminated environment. The CBX 
medicated animals were sacrificed at intervals over a 14-day withdrawal period. The mean 
urine : liver QCA concentration ratio in medicated animals subject to any form of 
withdrawal was found not to exceed 0.56 ± 0.21 (Mean ± SEM). The mean urine : liver 
QCA concentration in untreated animals, exposed to contaminated housing was found not 
to go beneath 10.59 ± 7.74 (Mean ± SEM). These results suggest that it is possible to 
differentiate between environmental contamination and deliberate medication on the basis 
on the urine : liver QCA concentration ratio. Tentative discriminatory criteria are 
suggested; CBX medicated animals that are subject to any withdrawal period would have 
a urine : liver QCA concentration of less than 0.80, whereas animals exposed to an 
environment contaminated with QCA would have a urine : liver QCA concentration
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greater than 4.5. Any samples falling within the range 0.9 - 4.4 should therefore be 
considered as inconclusive and subject to further investigation.
These criteria are based on a small number of animals. In the future, this study could be 
expended to allow a more accurate definition of these tentative limits with larger groups of 
animals and subsequently a larger number of results from different laboratories over a 
longer period.
6.5. Dual confirmation of quinoxaline carboxylic acid and methyl 
quinoxaline carboxylic acid in tissue
In pigs, liver and gastrointestinal enzymes degrade OQX to undetectable concentrations 48 
to 72 hours after the cessation of medication. Thus, the metabolite, MQCA, has been 
assigned as the marker residue for OQX use in liver. This allows the detection of OQX use 
in pigs several weeks after the cessation of medication. A current requirement within Eli 
is for a rapid, sensitive confirmatory method for MQCA in porcine tissue that will meet all 
EU criteria for method validation.
The aim of Chapter 5 was the development of a method for the confirmation of OQX use. 
Due to the chemical and structural similarity of QCA and MQCA, the extraction method 
previously described in Chapter 3 was adapted to include MQCA. This allowed the dual 
confirmation of both QCA and MQCA, the marker residues in liver for the use of CBX 
and OQX, respectively, within the same sample. Deuterated forms of both compounds (d4- 
QCA and dy-MQCA) were used as internal standards to improve the robustness of the 
method. The samples were subject to protease enzymatic digest, followed Iby two liquid- 
liquid extractions, clean up via solid phase extraction, and a further liquid-liquid extraction
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for concentration and preparation for HPLC. Narrow bore HPLC columns and gradient 
chromatography was employed to separate both compounds. Analysis was then carried out 
using HPLC linked via electrospray interface to tandem MS. The molecular ion [M + H]+ 
of QCA {m/z 175) produces two prominent product ions at m/z 102 and 75. The daughter 
ion, m/z 102, was used to calculate the QCA concentration by comparison to the internal 
standard (cLrQCA) ion, m/z 106, within the same sample and the standards. The molecular 
ion [M + H]+ of MQCA (m/z 189) produces two prominent product ions at m/z 145 and 
102. The daughter ion, m/z 145, was used to calculate the MQCA concentration by 
comparison to the internal standard (dv-MQCA) ion, m/z 152, within the same sample and 
the standards.
The method was again validated according to current Eli legislation. The accuracy, and 
precision of the method were demonstrated over the concentration range 3.0 - 150 pg kg'1 
for both analytes, to reflect the possible range of naturally incurred samples to be 
measured. An MRPL for QCA or MQCA has not yet been set. Thus, the method 
performance characteristics were assessed at a lower than expected concentration (2.0 pg 
kg'1) for both compounds; ensuring the method will meet any MRPL finally adopted by 
the EU. The assessed detection parameters, CCa and CCp have been calculated at 0.34 
and 0.57 pg kg'1, respectively, for QCA and at 0.82 and 1.44 pg kg'1, respectively, for 
MQCA.
This fast and robust method is to be applied to the statutory testing of National 
Surveillance Scheme samples in Nl.
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In the future, the developed method could be applied to establish if the metabolite of 
OQX, MQCA, can be transferred from medicated to untreated animals through exposure 
to a contaminated environment as laid out for QCA in Chapter 4. This would allow 
National Authorities to determine if a confirmed laboratory result for the presence of 
MQCA indicates conclusively the use of OQX by a producer. If such animal to animal 
transfer of residues is possible, the study could be extended to subsequently determine if it 
is possible to differentiate in the laboratory between animals subject to deliberate 
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